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Abstract  
Alzheimer’s disease is characterised by the histopathological presence of β-amyloid plaques 
and tau containing neurofibrillary tangles. Microglial activation is also a recognised 
pathological component. The relationship between microglial activation and protein 
aggregation is still debated. We investigated the relationship between amyloid plaques, tau 
tangles and activated microglia using PET imaging. Fifty-one subjects (nineteen healthy 
controls, sixteen mild cognitive impairment (MCI) and sixteen Alzheimer’s disease subjects) 
participated in the study. All subjects had neuropsychometric testing, magnetic resonance 
imaging (MRI), amyloid (
18
F-flutemetamol), and microglial (
11
C-PBR28) PET. All MCI and 
Alzheimer’s disease (AD) subjects and eight of the controls had tau (
18
F-AV1451) PET. 
11
C-
PBR28 PET was analysed using Logan graphical analysis with an arterial plasma input 
function, while 
18
F-flutemetamol and 
18
F-AV1451 PET were analysed as target: cerebellar 
ratios to create parametric Standardised Uptake Value Ratio (SUVR) maps. Biological 
parametric mapping (BPM) in the Statistical Parametric Mapping platform was used to 
examine correlations between uptake of tracers at a voxel-level.  
There were significant widespread clusters of positive correlation between levels of 
microglial activation and tau aggregation in both the MCI (amyloid positive and amyloid 
negative) and AD subjects. The correlations were stronger in AD than in MCI, suggesting 
that these pathologies increase together as disease progresses. Levels of microglial activation 
and amyloid deposition were also correlated, although in a different spatial distribution; 
correlations were stronger in MCI than Alzheimer’s subjects, in line with a plateauing of 
amyloid load with disease progression. Clusters of positive correlations between microglial 
activation and protein aggregation often targeted similar areas of association cortex, 
indicating that all three processes are present in specific vulnerable brain areas. For the first 
time using PET imaging, we show that microglial activation can correlate with both tau 
aggregation and amyloid deposition. This confirms the complex relationship between these 
processes. These results suggest that preventative treatment for Alzheimer’s disease should 
target all three processes.  
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Introduction 
Despite extensive research in recent decades, no cure has been identified for Alzheimer’s 
disease, and the precise mechanisms of the underlying pathologies are still unclear. Cardinal 
pathological features are amyloid β (Aβ) plaques and neurofibrillary tangles composed of 
hyperphosphorylated tau (Perl, 2010; Serrano-Pozo et al., 2011a). A third feature, which is 
also important in the disease process, is microglial activation. Microglial cells are the 
intrinsic macrophages of the central nervous system and are responsible for monitoring and 
responding to injury and insult in the surrounding brain (Pasqualetti et al., 2015). Activated 
microglial cells surround abnormally aggregated protein and are thought to represent the 
brain’s natural defence mechanism as they attempt to clear the protein fibrils. In Alzheimer’s 
disease and other neurodegenerative diseases, microglial activation becomes persistent and 
eventually ineffective (Heneka et al., 2015; Pasqualetti et al., 2015). In addition, the products 
of microglia chronically activated by aggregated Aβ (pro-inflammatory cytokines such as 
Tumour Necrosis Factor α, Interleukin-6, Interleukin-1α, Granulocyte Macrophage-Colony 
Stimulating Factor) can cause toxic damage to surrounding cells, the severity of which 
increases as disease progresses (Serrano-Pozo et al., 2016)(Serrano-Pozo et al., 
2016)(Serrano-Pozo et al., 2016). Histopathological studies have shown that activated 
microglial cells surround amyloid plaques (Perlmutter, 1990; Stalder et al., 1999) and 
neurofibrillary tangles (Sheffield, 2000; Serrano-Pozo et al., 2011b), possibly in an attempt to 
clear them. However, other studies suggest that microglial activation may be an early process 
in disease pathogenesis, causing abnormal protein aggregation (Yoshiyama et al., 2007; Lee 
et al., 2015). The precise role of microglial activation and in particular its relationship to 
amyloid deposition and tau aggregation is still debated. 
Given that amyloid deposition plateaus around the time of onset of symptoms (Villemagne et 
al., 2013) and that in established disease persistent microglial activation may lead to neuronal 
damage and tau aggregation (Sheffield, 2000), we hypothesised that levels of microglial 
activation would correlate with neurofibrillary tangle load in established Alzheimer’s disease, 
while in mild cognitive impairment, microglial activation would correlate with amyloid 
deposition. 
Positron Emission Tomography (PET) imaging allows us to detect and quantify microglial 
activation, amyloid deposition and tau aggregation in vivo, and provides spatial information 
about the extent of these molecular processes - information that was only previously available 
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at end stage post-mortem. Additionally, advanced image processing and quantification using 
Biological Parametric Mapping (Casanova et al., 2007) allows us to interrogate the inter-
relationship between these processes at a voxel level. 
18
F-flutemetamol PET is a marker of 
fibrillar amyloid β (Ikonomovic et al., 2016) while 
18
F-AV1451 PET is a high affinity marker 
of  paired helical filament-tau (Xia et al., 2013). 
11
C-PBR28 PET is a marker of translocator 
protein which is expressed by the outer mitochondrial membrane of the activated microglia 
associated with Alzheimer’s disease (Kreisl et al., 2013).   
The aim of this study was to evaluate in vivo the spatial inter-relationship between microglial 
activation, tau aggregation, and amyloid deposition in mild cognitive impairment and 
Alzheimer’s disease subjects.  
 
Materials and Methods 
Study population 
This study was approved by national and local ethics committees - the Riverside Research 
Ethics Committee, National Health Research Services, Health Research Authority, UK. 
Approval for administration of PET tracers was obtained from the Administration of 
Radioactive Substances Advisory Committee (ARSAC). Written informed consent was 
obtained from all subjects.  
Recruitment 
Subjects were recruited from local memory clinics, a national dementia recruitment website 
and advertisements in local media. After providing informed consent, subjects underwent a 
screening visit, and their clinical diagnosis of mild cognitive impairment and Alzheimer’s 
disease was confirmed after checking the clinical and neurological findings, MRI scans and 
neuropsychometric evaluation. The Petersen criteria (Petersen et al., 2004) were used for the 
diagnosis of mild cognitive impairment subjects, while NIA-AA (National Institute of Ageing 
and Alzheimer’s Association)(McKhann et al., 2011) or NINCDS-ADRDA (National 
Institute of Neurological and Communicative Disorders and Stroke-AD and Related 
Disorders Association criteria (McKhann et al., 1984) were used for the diagnosis of 
Alzheimer’s disease. Subjects were then stratified according to whether they carried one or 
two copies of the Ala147Thr polymorphism of the TSPO gene as high affinity binders, mixed 
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affinity binders, or low affinity binders of 
11
C-PBR28 (Owen et al., 2012). Low affinity 
binders were excluded from the study. 
Inclusion criteria were: 1) A diagnosis of mild cognitive impairment according to the 
Petersen criteria, or Alzheimer’s disease fulfilling NINCDS-ADRDA or NIA-AA criteria, or 
normal cognition for the healthy controls. 2) Age range 50-85 years. 3) Ability to give 
informed consent. 4) At least 8 years of formal education. 5) Mini-Mental Examination State 
score above 24 for mild cognitive impairment, above 15 for Alzheimer’s disease, and normal 
cognition for healthy controls. Exclusion criteria were: 1) History of major depression, or any 
significant disease influencing neuropsychological testing. 2) Schizophrenia or 
schizoaffective disorder. 3) Inability to undergo MRI scanning. 4) A malignancy within the 
last 5 years (except localised skin or prostate cancer). 
In total, fifty-one subjects (nineteen healthy controls, sixteen mild cognitive impairment and 
sixteen clinical Alzheimer’s disease subjects participated in the study. Along with 
neuropsychometric testing and MRI scanning, all subjects had 
18
F-flutemetamol PET, and 
eighteen of the nineteen had 
11
C-PBR28 PET. All mild cognitive impairment and 
Alzheimer’s disease subjects and seven of the controls had 
18
F-AV1451 PET. 
Image acquisition 
MRI 
Subjects had Magnetic Resonance Imaging (MRI) with a 3 Tesla Siemens Verio scanner and 
a 32-channel head coil. A T1-weighted magnetisation prepared rapid gradient echo sequence 
(MPRAGE; time repetition = 2400 ms, time echo = 3.06 ms, flip angle of 9, inversion time = 
900 ms, matrix = [256 x 246]) with a 1mm
3
 voxel size, anteroposterior phase encoding 
direction, and a symmetric echo was employed. Two subjects with coronary artery stents 
(who were therefore ineligible for 3 Tesla MRI) underwent 1.5 Tesla MRI with a Philips 
Achieva system (Best, Netherlands) at the MRC Clinical Sciences Centre, Imperial College 
London. 
 
PET imaging 
11
C-PBR28  
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11
C-PBR28 was manufactured at the Imanova Centre for Imaging Sciences in London and 
imaging was performed at the same centre with a Siemens Truepoint PET/CT (axial field of 
view of 21.8cm; 111 transaxial planes; spatial resolution of 2.056mm x 2.056 mm x 2 mm 
after image reconstruction). A mean dose of 330.9 (±30) MBq of 
11
C-PBR28 in 20ml normal 
saline was injected. Dynamic data was acquired in 3D and list mode over 90 minutes and the 
data was rebinned using the following time frames; 8x15 seconds, 3x60 seconds, 5x120 
seconds, 5x300 seconds, 5x600 seconds. Arterial blood was sampled (via a radial artery 
cannula) continuously with an online detector for the first 15 minutes and discrete blood 
samples were taken at 5, 10, 20, 30, 50, 70 and 90 minutes. Samples were centrifuged to 
measure whole blood and plasma radioactivity along with radioactive metabolite levels. 
Reverse-phase chromatography was used to analyse plasma metabolites.  Data reconstruction 
was performed by filtered back projection, (2.6 zoom, and 5mm Gaussian filter). 
18
F-flutemetamol 
18
F-flutemetamol was made by GE Healthcare, Amersham, UK. Scans were performed at 
Imperial College Clinical Imaging Facility using a Siemens Biograph 6 scanner with a 15cm 
field of view. A mean dose of 183.4 (±5.3) MBq of 
18
F-Flutemetamol was injected in 8ml 
saline followed by a 10ml saline flush. Data was acquired in 3D list mode from 90 to 120 
minutes following injection (6x5 minute frames). Image reconstruction was performed by 
filtered back projection with attenuation correction. Post reconstruction 5mm Gaussian 
smoothing was performed. The zoom was 2.6, the matrix size was 168x168 and the pixel size 
was 1.56mm x 1.56mm x 1.92mm. 
18
F-AV1451 
18
F-AV1451 was manufactured at Imanova Centre for Imaging Sciences, London, and scans 
were acquired using the same Siemens Truepoint PET/CT scanner as for 
11
C-PBR28 PET. A 
mean dose of 168.3 (±7.4) MBq 
18
F-AV1451 was injected in 20 ml saline. Data was acquired 
in 3D list mode for 120 minutes (frames of 8x15 seconds, 3x 60 seconds, 5x120 seconds, 
5x300 seconds, 8x600 seconds). Data reconstruction was performed with iterative 
reconstruction and 5mm Gaussian smoothing was applied post reconstruction. 
Image processing 
MRI and PET scans were pre-processed using Analyze AVW 11.0. Image processing was 
performed in Analyze AVW 11.0 and Statistical Parametric Mapping 5 (SPM5, Wellcome 
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Trust Centre for Neuroimaging, University College London) on a Matlab platform. Voxel 
level correlations were interrogated using the Biological Parametric Mapping toolbox, which 
is integrated into Statistical Parametric Mapping software. 
11
C-PBR28 parametric VT images 
were created with in-house MICK.exe parametric mapping software “MICK (Modelling, 
Input functions and Compartmental Kinetics) version 5.2 software (available on request from 
Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK (Dr Rainer 
Hinz)) was used to fit all regional compartmental models with the Nelder-Mead optimisation 
algorithm (Nelder and Mead, 1965). MICK uses MATLAB R2009bSP1 (The MathWorks, 
Natick, MA, USA)(Fan et al., 2016; McGinnity et al., 2017). 
11
C-PBR28 processing 
Logan graphical analysis was used to create parametric maps of VT at a voxel level using 
metabolite corrected arterial plasma input functions and dynamic PET time activity curves 
(TACs) for each subject. MICK software was used to generate a parametric map of 
11
C-
PBR28 VT from the slope of the Logan plot (Logan, 2000). The VT map was then co-
registered to the T1-weighted volumetric MRI scan, and transformed into Montreal 
Neurologic Institute standard space.  
18
F-Flutemetamol and 
18
F-AV1451 
The 90-120 minute summed 
18
F-Flutemetamol and 80-100 minute summed 
18
F-AV1451 PET 
images were co-registered to their T1-weighted MRI, and transformed into Montreal 
Neurological Institute space. The individual’s MRI was segmented into grey matter, white 
matter and cerebrospinal fluid (CSF) using Analyze AVW. Grey matter voxels were defined 
has having >50% probability of being grey matter and Analyze AVW was used to create 
individualised grey matter binary images. The binarised image was then convolved with the 
Hammers probabilistic atlas (Hammers, 2003) to create an individualised object map. The 
cerebellum was then sampled, and target-to-cerebellar uptake ratio images were produced by 
dividing the summed image by the uptake of cerebellar grey matter uptake in Analyze AVW. 
Region of interest analysis was performed by sampling these ratio images using 
individualised object maps. 
PET images were analysed both with and without a partial volume correction for reduction 
due to any atrophy present in the MRIs of mild cognitive impairment and Alzheimer disease 
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subjects. Partial volume correction was performed by structural-functional synergy for 
resolution recovery (SFS-RR) on a Matlab platform. (Shidahara et al., 2009) 
 
Voxel-level group comparisons 
 Normalised co-registered PET images (target:cerebellar ratio images for 
18
F-AV1451 and 
18
F-flutemetamol and Logan VT parametric maps for 
11
C-PBR28) for each disease group 
were compared to the controls using an independent t-test in SPM. A p value of <0.05 was 
considered significant, and no voxel extent threshold was used. For 
11
C-PBR28 PET, each 
group was compared to the respective control group according to binding status. 
Additionally, to identify whether each individual was ‘positive’ for tracer binding, a single-
subject comparison was performed in SPM as an independent t-test compared to the mean of 
the respective control group. 
 
Determining amyloid status 
Based on region of interest analysis of their SUVR 
18
F-Flutemetamol images, subjects were 
classified as amyloid positive or negative. Subjects were classified as amyloid positive if they 
had increased binding (compared to control mean + 2 standard deviations) in one or more 
cortical regions (frontal, parietal, temporal, occipital lobe, anterior cingulate and posterior 
cingulate cortex). This was confirmed on visual read. Subjects were deemed positive for tau 
tangles and microglial activation if they had increased tracer binding (relative to control mean 
+ 2 standard deviations) in the left or right hippocampus, parahippocampus, amygdala, 
fusiform gyrus, temporal lobe, frontal lobe, parietal lobe, or occipital lobe. 
 
Generation of Z-score maps and voxel-level correlations using biological 
parametric mapping analysis 
The biological parametric mapping toolbox (Casanova et al., 2007) was used to create Z-
score maps of tracer uptake for each subject. Generating tracer Z-maps for each subject 
allows spatial correlations between the uptake of the different tracers with different means 
and variances to be interrogated and reveals the inter-relationships of each Alzheimer 
pathology. 
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The Z-score maps were created in SPM5 using the following formulae: 
Z score (
11
C-PBR28 VT) = (
11
C-PBR28 Logan VT of individual – Mean of the control 
11
C-
PBR28 Logan VT )/Standard deviation of 
11
C-PBR28 control Logan VT 
Z score (
18
F-flutemetamol) = Individual 
18
F-flutemetamol ratio image - control mean of 
18
F-
flutemetamol ratio/standard deviation of control 
18
F-flutemetamol 
Z-score (
18
F-AV1451) = individual 
18
F-AV1451 ratio – control mean of 
18
F-AV1451 
ratio/standard deviation of control 
18
F-AV1451 
For 
11
C-PBR28 images, Z-maps were generated from the appropriate control cohort 
according to the TSPO binding status of each subject.  
11
C-PBR28 uptake of mild cognitive 
impairment and Alzheimer’s disease cases who were high or mixed affinity binders was 
compared with mean uptake of the high or mixed affinity binders in the control group. After 
Z-maps were generated (so accounting for effects of binding status), the medium and high 
affinity binders were then combined for analysis as one group. 
The voxel-level correlations between microglial activation, amyloid load, and tau aggregation 
were interrogated across individual Z-score maps using the Biological Parametric Mapping 
toolbox for all groups. To assess significance of correlations between 
18
F-Flutemetamol and 
11
C-PBR28 uptake, and 
18
F-AV1451 and 
11
C-PBR28 uptake in the amyloid negative subjects, 
a statistical threshold was set at p<0.05 with an extent threshold of 500 voxels. Given the 
highly significant positive correlations between 
18
F-AV1451 and 
11
C-PBR28 in the amyloid 
positive mild cognitive impairment and Alzheimer’s disease groups, we set the cluster level 
of significance at 0.01, and the extent threshold at 500 voxels for these correlation analyses. 
All clusters with a corrected p-value of p<0.05 were considered significant. P-values were 
corrected for family-wise errors. 
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Results 
Demographics 
All nineteen healthy controls in our fifty-one subjects scanned were amyloid negative.  Nine 
mild cognitive impairment subjects were amyloid positive while seven were negative. Of the 
sixteen subjects with a clinical diagnosis of Alzheimer’s disease, fourteen were amyloid 
positive and two were negative. These two subjects had a clinical diagnosis of probable 
Alzheimer’s disease based on the NINCDS-ADRDA criteria, but had negative amyloid PET 
scans. Both individuals had impaired neuropsychometric tests in multiple domains that 
affected activities of daily life. The MRIs of both subjects showed reduced hippocampal 
volume. Their diagnoses had been made in a hospital clinic settings, and was reconfirmed on 
the initial screening visit. 
Table 1 shows the demographic and neuropsychometric details of the cohort. As expected, 
neuropsychometric tests revealed impaired scores for both mild cognitive impairment and 
Alzheimer’s disease subjects. The mean delay between 
18
F-flutemetamol and 
11
C-PBR scans 
was 2.1 months; and 
18
F-AV1451 and 
11
C-PBR28 scans was 8 months. The amyloid positive 
MCI subjects were significantly older than the amyloid negative subjects, with significantly 
worse delayed visual recall, delayed word list recall and semantic fluency.  
Voxel-level group differences 
Figure 1 shows the voxel-level distribution of increased 
18
F-flutemetamol, 
18
F-AV1451 and 
11
C-PBR28 uptake (only the high affinity binders are shown for 
11
C-PBR28 as these 
represented the majority of these cases – eight of the Alzheimer’s disease cases, four of the 
mild cognitive impairment cases and seven of the amyloid negative cases compared to the 
control group). 
 Although the clusters show trends for increased uptake, there were no significantly increased 
clusters in the Alzheimer’s disease or amyloid negative group compared to the controls at a 
group level.  
However, when we examined tracer uptake for each individual compared to the control 
group, distinct binding patterns emerged. In the Alzheimer’s disease group (all of whom were 
amyloid positive), five had increased tau and microglial activation; nine only had increased 
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tau. In the amyloid positive mild cognitive impairment group, four had increased tau, while 
two had increased microglial activation and one had both increased tau and microglial 
activation. In the amyloid negative group, three individuals had increased tau and microglial 
activation, two had increased microglial activation and one had increased tau only. Clusters 
of each individual’s increase binding for 
11
C-PBR and 
18
F-AV1451 are shown in 
Supplementary table 4. There were six individuals (five Alzheimer’s disease and one amyloid 
positive MCI) who had increased binding of all three tracers. 
 In order to visually display the spatial distributions of tracer binding, the mean summed 
images are shown for each group and each tracer in Supplementary Figure 1. Data for the 
eighteen healthy control subjects who had 
11
C-PBR28 PET (eleven high affinity binders and 
seven mixed affinity binders) are shown in Supplementary figure 4). 
Voxel-level correlations 
There were clusters of highly significant positive correlations throughout the cortex between 
microglial activation and both tau aggregation and amyloid deposition in the Alzheimer’s 
disease and mild cognitive impairment subjects (shown in Figures 2 and 3). There were 
extensive clusters of positive correlations, with a larger area of involvement and higher Z-
scores, between microglial activation and tau aggregation compared with microglial 
activation and amyloid deposition. There were also clusters of positive correlations between 
microglial activation and tau aggregation in the amyloid negative group throughout the 
isocortex. (Figure 2) 
Tau and microglial activation (Amyloid positive individuals) 
Positive correlations between 
18
F-AV1451 and 
11
C-PBR28 uptake are shown in 
Supplementary Table 1. In the mild cognitive impairment group, there were positive 
correlations in the frontal, temporal, parietal and cingulate but not the occipital cortices. The 
strongest correlations in the group, with the highest Z-scores and correlation coefficients, 
were in the frontal lobe.  
In the Alzheimer’s disease group, there were significant positive correlations between 
18
F-
AV1451 and 
11
C-PBR28 uptake in the frontal, temporal, parietal, occipital, and insular 
cortices. The strongest correlations were seen in the frontal and temporal lobes and the Z-
scores were higher in the Alzheimer’s disease compared to the MCI group, indicating 
increasing tau-inflammation correlations at voxel level as the disease advances. 
Page 12 of 93
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
The clusters of positive correlations in the temporal lobe differed between the mild cognitive 
impairment and Alzheimer’s disease groups: the mild cognitive impairment group had 
positive clusters in the posterior temporal lobes and left fusiform gyrus while the distribution 
was more diffuse in the Alzheimer’s disease group – the anterior, posterior, lateral (fusiform 
gyrus) and medial temporal (amygdala and hippocampus) lobes all had clusters of significant 
correlation (Table 2). 
Examples of correlation plots from individual single voxels within clusters are shown in 
Supplementary Figure 3.  Correlation plots from the voxels with the highest Z-scores and 
correlation coefficients have been illustrated. 
Amyloid negative individuals 
There were two individuals with a clinical diagnosis of Alzheimer’s disease who were 
amyloid negative. The results for these subjects were combined with the amyloid negative 
mild cognitive impairment individuals when performing the Biological Parametric Mapping 
correlation analysis, as they were likely to represent non-Alzheimer syndromes. Individual 
voxel level increases of tau aggregation and microglial activation for the nine individuals are 
shown in Figure 5. Positive correlations are shown in Supplementary Table 1.  
Tau aggregation and microglial activation were positively correlated in this group, with 
clusters in the right superior parietal gyrus, left posterior temporal lobe, left lateral part of 
occipital lobe and right superior frontal gyrus. The areas of positive correlation were smaller 
with lower Z-scores and lower correlation coefficients than those seen for the amyloid 
positive groups.  
Amyloid and microglial activation (Amyloid positive individuals) 
There were positive correlations throughout the cortex in both Alzheimer’s disease and mild 
cognitive impairment subjects. However, MCI subjects showed more extensive regions of 
correlation with higher correlation coefficients and Z-scores compared to the Alzheimer’s 
disease group. The most widespread distribution of positive correlations in the mild cognitive 
impairment group was in the frontal and temporal cortex, while in the Alzheimer’s disease 
group, the parietal cortex had the widest distribution of clusters. The locations of regions of 
positive correlations are shown in Supplementary Table 1 and Figure 3. 
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Regions where microglial activation correlated with both tau aggregation and 
amyloid deposition  
Certain regions had clusters of positive correlations between microglial activation and both 
amyloid deposition and tau aggregation across all the groups (mild cognitive impairment and 
Alzheimer’s disease, amyloid positive and negative). These regions included the posterior 
temporal lobe and superior frontal gyrus. Other regions that were commonly affected in more 
than one group were the lateral part of the occipital lobe and inferolateral part of the parietal 
lobe. 
Tracer positive individuals only 
Next, to ensure that our correlations were not false positives arising from inclusion of ‘null 
data points’ from tracer negative individuals, and to address the fact that there were not 
significant differences between the AD group and controls, we analysed the six individuals  
(one mild cognitive impairment and five Alzheimer’s disease individuals) who were positive 
at voxel level for binding of all three tracers. As the number of these subjects was small, they 
were analysed as a single group. Correlations are shown in Supplementary Table 2a, and 
group differences with controls for each tracer are shown in Supplementary Table 2b. 
Individual levels of microglial activation correlated strongly with levels of both amyloid 
deposition and tau aggregation across the cortex, with Z-scores above 4 (Figure 4). The 
clusters with the strongest correlations between amyloid and microglial activation were 
localised in the precentral, inferior and middle frontal gyri. The strongest correlations 
between tau and microglial activation were localised in the superior, middle and inferior 
frontal gyri. 
The clusters of positive correlations between tau and microglial activation were of a similar 
size, correlation strength and distribution in this small sub-group. 
Partial volume correction of images 
Clusters of correlated uptake across the tracers using partial volume corrected images are 
shown in Supplementary Table 3 and Supplementary Figure 2. Interestingly, when partial 
volume correction was applied, the correlations became more widespread and showed higher 
Z-scores and r-correlation coefficients than the non-partial volume corrected images. The 
pattern of positive correlations, and the stronger correlation between microglial activation and 
tau aggregation in Alzheimer’s disease than mild cognitive impairment persisted. 
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Discussion 
In this first reported PET study to examine microglial activation, tau aggregation and amyloid 
deposition in subjects with mild cognitive impairment and Alzheimer’s disease, we found 
clusters where microglial activation is strongly correlated at a voxel level with both tau 
aggregation and amyloid deposition. There were also significant positive correlations 
between tau aggregation and microglial activation in our amyloid-negative cognitively 
impaired group. 
Correlations between tau aggregation and microglial activation were stronger in the 
Alzheimer’s disease group compared to the mild cognitive impairment group, with higher Z-
scores, higher correlation coefficients (r) and a wider distribution of clusters, particularly in 
the temporal lobe where tau aggregation is known to increase in intensity through the Braak 
stages (Braak and Braak, 1991). These findings support previous histopathological and in 
vitro studies, which have shown that microglial activation parallels tau aggregation as disease 
progresses (Sheffield, 2000; Serrano-Pozo et al., 2011b). In addition, microglial activation 
correlates with the spread of tau aggregation in the brain (Maphis et al., 2015b). The pro-
inflammatory products of microglial activation promote tau hyperphosphorylation in vitro  
(Quintanilla et al., 2004; Gorlovoy et al., 2009; Lee et al., 2010; Maphis et al., 2015b), which 
in turn induces tau neurofibrillary tangle formation; this may then cause further microglial 
activation, (Zilka et al., 2009) resulting in a positive feedback cycle as disease progresses 
(Figure 6). This could apply to our mild cognitive impairment/Alzheimer’s disease cohort, 
however, longitudinal studies are needed to provide more insight into mechanisms driving 
progression of disease rather than a cross-sectional study. 
Clusters of correlations between amyloid and microglial activation were predominantly 
localised in the isocortex – that is the frontal, temporal, parietal and occipital, insular and 
anterior cingulate cortices. These findings support previous histopathological findings that 
have described microglia surrounding cortical amyloid plaques (Perlmutter, 1990; Stalder et 
al., 1999). Interestingly, the area of distribution was wider and the strength of correlations 
was higher in the mild cognitive impairment subjects compared to the Alzheimer’s disease 
group. This may be because amyloid deposition occurs early in the disease process triggering 
microglial activation in an attempt to clear the plaques. A peak of early microglial activation 
could occur when amyloid deposition first takes place a decade before symptoms appear 
(Villemagne et al., 2013) followed by a decline in microglial activation as amyloid load 
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plateaus followed by a second peak as neurofibrillary tangles form and intensify across the 
cortex (Serrano-Pozo et al., 2011b). 
The fact that tau aggregation and microglial activation were correlated in our amyloid 
negative individuals (albeit less strongly than in the amyloid positive individuals) suggests 
that amyloid is not necessary for a cycle of tau tangle – activated microglia – tau tangle 
feedback. Microglial activation may drive tauopathies playing a similar underlying 
pathogenic role to that in Alzheimer’s disease – that is, promoting tau hyperphosphorylation 
and propagation in the brain. This is in line with previous in vivo findings of increased 
microglial activation in tauopathies (Paulus et al., 1993; Ishizawa and Dickson, 2001; 
ishizawa et al., 2004). The consistent pattern of inflammation seen in cognitively impaired 
tau positive individuals who were positive and negative for amyloid, suggests that the 
findings are not due to false positives. 
Two amyloid negative dementia subjects had a clinical diagnosis of Alzheimer’s disease 
based on NINCDS-ADRDA criteria, and cognitive impairment in multiple domains, affecting 
activities of daily life. Both had evidence of elevated 
18
F-AV1451 binding in the temporal 
lobe substructures (on sampling of the ratio image), and both had elevated 
11
C-PBR28 VT 
calculated from a two tissue compartment model (data not shown). While these individuals 
are unlikely to have Alzheimer’s disease (according to their biomarker profile), they 
represent a significant proportion of Alzheimer’s disease ‘mimics’. Clinical trials and autopsy 
studies show that 15%-16% of individuals with a diagnosis of ‘probable Alzheimer’s disease’ 
have insufficient neuropathological changes to confirm the diagnosis (Salloway et al., 2014; 
Serrano-Pozo et al., 2014). Notably, when examining the distributions of tau aggregation and 
microglial activation in each of the nine individuals, the distributions and patterns of each 
tracer differed, emphasising the heterogeneity of pathologies in these individuals. ). This 
group was small, with only three individuals demonstrating increased binding of both 
11
C-
PBR28 and 
18
F-AV1451, and there were no group mean  differences from the controls in 
either pathology. However, five individual subjects had increased microglial activation and 
four had increased tau aggregation compared with the controls, emphasising the 
heterogeneity of pathologies in these individuals. One possible diagnosis could be Primary 
Age-related Tauopathy (PART) where isolated neurofibrillary tangles are localised to the 
medial temporal lobe, across a spectrum of cognitive ability (Crary et al., 2014), although 
microglial activation has not been reported in this condition. Microglial activation can play a 
role in other neurodegenerative diseases such as dementia with Lewy bodies, frontotemporal 
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dementia and Parkinson’s disease (Cagnin et al., 2004; Surendranathan et al., 2015). 
Additionally, mixed pathologies in the ageing brain are very common (Schneider et al., 2009) 
and the relationship between microglial activation and other senile pathologies such as 
TDP43 aggregation, hippocampal sclerosis and argyrophilic grain disease are still unknown. 
Finally, small vessel disease can be associated with microglial activation which is a well-
recognised subacute response to stroke (Vidale et al., 2017; Zhao et al., 2017) and occurs 
after cerebral hypoperfusion in mice (Manso et al., 2017). Thus, the presence of microglial 
activation in both patients with and without amyloid may be related to independent processes 
altogether, with tau hyperphosphorylation representing the end of a final common pathway.  
Although this study was not longitudinal so inferences about temporal changes in the disease 
process cannot be made, it is interesting that amyloid load correlated with inflammation 
levels most strongly in mild cognitive impairment whereas tau load correlated most strongly 
with inflammation levels in Alzheimer’s disease by which time amyloid plaque load has 
plateaued but tau tangles are still increasing.  In vitro studies suggest that microglial 
activation may actually cause up-regulation of both tau and amyloid pathology (Lee et al., 
2015), again supporting the positive feedback mechanism, and explaining the rapid 
progression of cortical neurofibrillary tangles in Alzheimer’s disease. Furthermore, tau 
protein  in a pathological form may actually be required for microglia-induced cell toxicity, 
showing again the complex inter-play between the pathologies (Maphis et al., 2015a). While 
the clusters of positive correlations are indicative of the relative timing of pathologies – that 
is that peaks of microglial activation occur as first amyloid and then tau aggregation increases 
in the cortex - the exact temporal and spatial patterns of disease cannot be inferred from this 
cross sectional data and a longitudinal follow up study is required.  
While our data shed some light on the relative distributions and correlations of microglial 
activation in mild cognitive impairment and Alzheimer’s disease, the relationship between 
amyloid plaques, tau tangles and microglial activation is clearly complex. Recent reports 
suggest that cortical amyloid plaque deposition is required to promote  isocortical, though not 
subcortical, tau aggregation in a synergistic manner so driving disease progression (Pascoal et 
al., 2016). Recent biomarker studies (Pontecorvo et al., 2017) and older histopathological 
work (Price and Morris, 1999) show that amyloid deposition and tau aggregation start 
independently of each other (amyloid in the isocortical areas, tau neurofibrillary tangles in the 
medial temporal lobe), but that the spread of tau to the isocortical areas is dependent on the 
presence of amyloid fibrils. The spatial dissociation of this synergism is unexplained, but 
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may be due to amyloid cross-seeding tau along functional networks and precipitating tau 
spread (Vasconcelos et al., 2016). The role of microglial activation is likely to be critical in 
this process – for example, microglial cells activated by amyloid plaques may induce further 
tau hyperphosphorylation, inducing further neurofibrillary tangles and initiating tau spread 
across the cortex, leading to Alzheimer’s disease (represented in figure 6). It is important to 
note that not all areas follow this model, and imaging data may not fully reflect the spectrum 
of heterogeneity of pathology in Alzheimer’s disease. Hopefully, autoradiographic and 
histopathological follow up of our imaging dataset will provide support for this hypothesis. 
Microglial activation may at times play a protective role: a mouse study crossing transgenic 
amyloid and transgenic tau mice produced offspring with increased microglial activation (and 
increased phagocytic ability), and a 40-50% reduced plaque load, implying that under certain 
circumstances tau –induced microglia activation clears amyloid load (Chen et al., 2016). 
However, current PET tracers are unable to differentiate between protective or detrimental 
roles of activated microglia. 
The use of 
11
C-PBR28 PET as a marker of TSPO expression and, indirectly, microglial 
activation should also be discussed. 
11
C-PBR28 has a subnanomolar affinity for a binding site 
on TSPO expressed by the mitochondria of activated microglia which is eighty times higher 
than the affinity of the first generation ligand 
11
C-PK11195 (Kreisl et al., 2010). It has 
differentiated Alzheimer’s disease from healthy controls in several studies (Kreisl et al., 
2013; Lyoo, 2015) but no studies to date have shown increased uptake in mild cognitive 
impairment subjects. Binding has been shown to increase with Alzheimer disease progression 
(Kreisl et al., 2016), and has been shown to correlate with extent of neurodegeneration in the 
primary visual cortex of Posterior Cortical Atrophy cases. (Kreisl 2017). However, there are 
also limitations. No studies to date have shown group regional VT differences between AD, 
MCI and controls. High variability is also a feature of 
11
C-PBR28 PET(Cumming et al., 
2018)):  A study in healthy controls showed high test-retest variability (15.9+/-12.2%), high 
inter-subject variability and significant differences in results when scanning the same 
subjects in the morning and afternoon (Collste et al., 2016). However, another study 
examining 11C-PBR28 in multiple sclerosis found a lower absolute mean test-retest 
variability ranging from 7-9%. (Park et al., 2015). Other studies have shown that there are 
significant correlations between peripheral leucocyte count and brain TSPO binding, 
suggesting that TSPO expression may be susceptible to systemic immune changes. 
(Kanegawa et al., 2016) The variable free fraction of tracer in the plasma may introduce 
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another source of variance. This variability may be one reason for the lack of group 
differences between the AD group and healthy controls in our cohort. Moreover, a blocking 
study showed tracer binding throughout the brain, indicates that there is no region in the brain 
that is truly devoid of binding that can be used as a reference for non-specific binding (Owen 
et al., 2014).  
Furthermore, there is evidence that levels of microglial activation fluctuate with Alzheimer’s 
disease progression(Fan et al., 2017). There is evidence of increased microglial activation 
early on(Hamelin et al., 2016), which plateaus(Lopez-Picon et al., 2017), followed by further 
activation later in the disease course(Fan et al., 2017). Our cohort was imaged at a single time 
point so it is not possible to ascertain the exact stage of disease trajectory that each individual 
is on, with a mean MMSE score of 22, our AD cohort had relatively mild or ‘intermediate’ 
disease, which may also explain the low levels of microglial activation in some individuals 
and the lack of group difference.  
The TSPO receptor is used as a biomarker marker for neuroinflammation but, as well as 
being expressed by activated microglia, TSPO can also become upregulated in other cells 
including astroglia and neurons. It is possible that the correlations we see with PBR28 PET 
between intra-cellular tau tangle and activated microglia load reflect TSPO expression by 
dystrophic neurons, however, histopathological studies on Alzheimer brains would be against 
this. Rather, our results are in line with histopathological studies that show activated 
microglia surround neurofibrillary tangles (Sheffield, 2000; Serrano-Pozo et al., 2011b). 
Autoradiographic studies are required to confirm that our results do not represent false-
positive co-localisation. Finally, a recent study examining the effects of myeloid cell 
activation on TSPO expression found that activation of pro-inflammatory macrophages in 
humans is associated with a reduction in TSPO expression (in contrast to rodents, where the 
converse was seen) (Owen et al., 2017). This study indicates a possible limitation in using the 
TSPO receptor as a neuroinflammation marker. 
Several different analytical methods have been used with 
11
C-PBR28 PET. Studies have 
reported conflicting results, which is partly due to different methodological approaches. 
Groups have corrected VT for the free fraction of 
11
C-PBR28 in plasma and reported 
significant differences between patients and control subjects (Kreisl et al., 2013). Other 
groups have used the cerebellum as a ‘pseudo-reference region’, arguing that Alzheimer 
pathology occurs late in the cerebellum so any pathological changes in early cases will be 
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seen in the isocortex. (Lyoo, 2015). Groups using 
11
C-PBR28 PET to study other diseases 
have used ‘whole brain binding’ as a reference region (Bloomfield et al., 2016) in order to 
reduce variance due to genotypic and plasma protein binding variability. However, as there is 
no cortical region devoid of translocator protein, this approach will act to diminish observed 
relative changes in target regions.  A whole brain reference region of interest will also reflect 
signal from white matter and subcortical structures (Narendran and Frankle, 2016). 
Another factor to consider with
 11C
-PBR28 is correction for free fraction of the tracer in 
plasma (fP, which may account for some of the variability introduced by plasma input 
function). 
In our cohort, fP ranged from 0.78% to 2.89%, and there were no significant differences in 
fP between the three groups. (mean value for free fraction of tracer in plasma = 1.829, 
standard deviation 0.478; coefficient of variation 26%). This high variability is similar to 
previous reports (Hines et al., 2013; Rizzo et al., 2014). Some authors argue that the very 
small values of fP can lead to inaccuracies in measurement and laboratory error. (Rizzo et 
al., 2014; Turkheimer et al., 2015). The effect of fP levels only becomes critical, however, if 
exchange rates of 
11
C-PBR28 on and off plasma proteins is of the same order or slower than 
its rate of brain uptake. Generally exchange of tracers on and off plasma proteins is rapid 
compared to rates of their brain uptake and so has relatively little influence on brain VTs. 
Having said that,  a study using 
11
C-PK11195 found that this isoquinoline tracer strongly 
bound to some  plasma proteins which are upregulated in inflammatory diseases. (Lockhart 
et al., 2003) This may confound measurement of TSPO binding in inflammatory diseases such 
as Alzheimer’s disease. 
As such, and in view of the lack of consensus agreement about whether VT or VT/fP is 
superior, (Cumming et al., 2018) we have reported VT (rather than VT/fP). 
 
Thus, it is clear that there are limitations associated with the use of 
11
C-PBR28 PET, and 
results should be interpreted with caution. In view of the fact that there is no true reference 
region in the brain for TSPO binding, we chose to compute absolute quantification using an 
arterial plasma input function as this remains the gold standard for PET analysis. 
One of the strengths of our study is that our disease groups were clinically well characterised 
with detailed neuropsychometric evaluation and known amyloid status. In addition, we used 
an arterial input function to analyse 
11
C-PBR28 VT. We also accounted for the differential 
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binding status of subjects for 
11
C-PBR28 due to differential expression of TSPO 
polymorphisms (Owen et al., 2012; Kreisl, 2013; Yoder et al., 2013) by creating z-maps for 
each individual’s binding compared to the controls. This allowed all subjects to be examined 
as a group whether classified as MAB or HAB. We excluded the low affinity binders from 
the study (due to their negligible binding) but it has recently been demonstrated that binding 
status is not associated with clinical status, therefore conclusions from a subgroup can be 
applied to a whole cohort. (Fan, 2015) However, the spectrum in binding affinity remains a 
limitation of the second generation TSPO tracers, and other unidentified genetic sources of 
variation may also be present. 
One of the limitations of our study was that for the 
11
C-PBR28 and 
18
F-flutemetamol PET 
scans, the mild cognitive impairment and Alzheimer’s disease groups were significantly older 
than our healthy control group. While some studies have suggested that microglial activation 
increase with age (Kumar et al., 2012; Walker et al., 2015), other PET studies have not 
detected a significant increase with age (Suridjan et al., 2014). Additionally, we did not find a 
correlation between microglial activation and age in our healthy control group. Secondly, due 
to patient and scanner availability and the onerous nature of the study, there were time delays 
between scans. During these months, the pathological processes may have progressed, but we 
assume this would not have been considerable given the long duration of these processes. 
Individuals taking benzodiazepines were excluded from the study. One individual in the 
Alzheimer’s disease group was taking a non steroidal anti-inflammatory medication and it 
was not recorded whether a dose was taken on the day of the scan. This may represent a 
potential confound affecting 
11
C-PBR binding, although this individual had significantly 
higher uptake than the mean +2 standard deviations of the control group. 
Additionally, while the correlations between tracer binding in this cohort are intriguing, we 
acknowledge the fact that there were no significant between group mean differences between 
the Alzheimer’s disease group and amyloid negative group and healthy controls. This is a 
limitation of the study, and may be due to the high variability in 
11
C-PBR28 described above, 
the dynamic nature of microglial activation or the fact that the study is small and 
underpowered to detect group level differences, particularly when subdividing groups 
according to amyloid status, disease group and binding status. However, our sub-group 
analysis of tracer positive individuals confirmed that correlations across tracer uptake did not 
artefactually arise from ‘null data points’ from tracer negative individuals.  
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We acknowledge that the numbers used in the study are too small to make a definitive 
conclusion about the distribution of these processes in Alzheimer’s disease. This is 
particularly apparent when dividing groups according to disease status and amyloid status. If 
we had larger numbers of individuals with increased binding of all three tracers, a more 
robust correlative analysis could be performed. However these findings are important and 
may guide future work in this direction. 
It should also be noted that while we have demonstrated correlations between tracer binding, 
off-target binding has been reported for 
18
F-AV1451 in the midbrain, lateral geniculate 
nucleus, choroid plexus, basal ganglia, substantia nigra, meninges, retina and melanin 
containing cells (Marquie et al., 2015; Lowe et al., 2016). However, this off-target binding is 
also likely to be present in both patients and controls and the interrogation of Z-score maps 
should help correct for this.  
Finally, recent work has shown that 
18
F-flutemetamol only detects later stages of amyloid 
deposition, universally missing Thal stages 1 and 2, and some Thal stage 3 cases (Thal et al., 
2015). Consequently, some of the individuals in our ‘amyloid negative’ group could have had 
early Alzheimer’s pathology, biasing correlations between tau and microglial activation 
towards a positive outcome.  
Implications and future directions 
Our findings suggest that levels of microglial activation can correlate with tau tangle and 
amyloid plaque load in mild cognitive impairment and Alzheimer’s disease. This suggests 
that microglial activation may play a role in propagating disease pathology in Alzheimer’s 
disease. Certain areas of the brain are clearly more vulnerable to Alzheimer’s pathology - 
microglial activation correlated with both amyloid deposition and tau aggregation in the 
posterior temporal lobe and superior frontal gyrus.  
An important further area of study would focus on the cognitively healthy older control 
group, to detect tracer binding and pathological correlations not yet reaching clinical 
significance.  
Further longitudinal studies in these subjects to evaluate the progression and distribution of 
the pathologies would allow us to better understand their underlying temporal inter-
relationships. 
Conclusion 
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This is the first PET study to examine pathological correlations between levels of microglial 
activation and aberrant protein aggregation in mild cognitive impairment and Alzheimer’s 
disease. We found that microglial activation correlates strongly with tau aggregation in 
established Alzheimer disease and, to a lesser extent with amyloid deposition. In contrast, 
microglial activation correlates more strongly with amyloid deposition in MCI. These 
findings support previous in vitro findings and confirm the complex relationships between 
these pathological processes in Alzheimer’s disease. Our findings suggest that a multi-
targeted approach will be necessary for an effective therapeutic intervention. 
 
Figures and tables 
Table 1 Demographics of the study cohort 
Figure 1 Voxel level increases in 
18
F-flutemetamol (Fig 1A and 1B), 
18
F-AV1451 (Fig1C, 
1D and 1E) and 
11
C-PBR28 High Affinity Binders (Fig1F, 1G and 1H) compared to the 
healthy controls using independent t-test in SPM. For 
18
F-flutemetamol and 
11
C-PBR28, a 
threshold of significance of p<0.05 was used. For 
18
F-AV1451, a threshold of significance of 
p<0.01 was used. These images show the distribution of pathology in the mild cognitive 
impairment and Alzheimer’s disease groups. 
Figure 2 Voxel level correlations between tau and microglial activation in the amyloid 
positive mild cognitive impairment (Fig 2A), Alzheimer’s disease (Fig 2B) and amyloid 
negative cognitively impaired individuals (Fig 2C) 
Figure 3 Voxel level correlations between amyloid and microglial activation in the amyloid 
positive mild cognitive impairment (Fig 3A) and Alzheimer’s disease (Fig 3B) individuals 
Figure 4 Voxel level correlations in the tracer positive individuals only, between microglial 
activation and tau aggregation (Figure 4A) and microglial activation and amyloid deposition 
(Figure 4B). 
Figure 5 Individual parametric maps (Individual 1-9) of microglial activation (A) and tau 
aggregation (B) in the nine amyloid negative individuals with cognitive impairment, 
compared to the control mean. Clusters show trends of increased binding. Individuals 1,2,4,5 
and 6 had statistically significant clusters of 
18
F-AV1451 binding, while individuals 1,2,3,4 
and 6 had statistically significant 
11
C-PBR28 binding compared to the control groups. This 
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figure is provided to illustrate distributions of the pathologies in this small group of 
individuals. 
Figure 6 The vicious cycle of activated microglia and protein aggregation. Activated 
microglia surround amyloid plaque and neurofibrillary tangles, and in turn promote 
upregulation of amyloid plaque and tangles. Further, the pro-inflammatory products of 
activated microglia promote further tau hyperphosphorylation and spreading of 
neurofibrillary tangles throughout the cortex 
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Supplementary information 
Supplementary Table 1 Clusters of positive correlations between 
11
C-PBR 28 and 
18
F-
AV1451 and
 18
F-flutemetamol 
Supplementary Table 2a Clusters of voxel-level positive correlation between 
18
F-
Flutemetamol and 
11
C-PBR28 in individuals positive for all 3 tracers 
Supplementary Table 2b Voxel level comparisons between the tracer positive individuals 
and healthy controls for each tracer 
Supplementary Table 3 Clusters of positive correlation between 
11
C-PBR28 and 
18
F-
AV1451 and 
18
F-flutemetamol after partial volume correction 
Supplementary table 4 Individual clusters of increased binding of 
18
F-AV1451 and 
11
C-
PBR28. In the Alzheimer’s disease group (all of whom were amyloid positive), five had 
increased tau and microglial activation; nine had increased tau. In the amyloid positive mild 
cognitive impairment group, four had increased tau, while two had increased microglial 
activation and one had increased tau and microglial activation. In the amyloid negative group, 
three individuals had increased tau and microglial activation, two had increased microglial 
activation and one had increase tau only. 
Supplementary Figure 1 Mean colourmap images for controls, mild cognitive impairment 
and Alzheimer’s disease individuals for all three processes. Figures 4A-4D show mean 
18
F-
AV1451 uptake (controls, mild cognitive impairment, Alzheimer’s disease, Amyloid negative 
individuals respectively); Figures 4E-4H show 
11
C-PBR28 (controls, mild cognitive 
impairments, Alzheimer’s disease, Amyloid negative individuals, respectively) and Figures 
4I to 4K show mean 
18
F-flutemetamol uptake (controls, mild cognitive impairment and 
Alzheimer’s disease). 
 
Supplementary Figure 2 Partial volume corrected positive correlations between 
11
C-PBR28 
and 
11
F-flutemetamol in mild cognitive impairment (A) and Alzheimer’s disease (B), and 
between 
11
C-PBR28 and 
18
F-AV1451 in mild cognitive impairment (C), Alzheimer’s disease 
(D) and the amyloid negative cognitively impaired individuals (E) 
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Supplementary Figure 3a Correlation plots of individual voxel binding between 
11
C-PBR28 
and 
18
F-AV1451  in the mild cognitive impairment group (Figures A and B)) 
 
Supplementary Figure 3b Correlation plots of individual voxel binding between 
11
C-PBR28 
and 
18
F-AV1451 in the Alzheimer’s disease (Figures C, D and E) and amyloid negative 
individuals (Figure F). 
 
Supplementary Figure 3c Correlations between 
18
F-flutemetamol and 
11
C-PBR28 are shown 
in the mild cognitive impairment group (Figures G and H) and Alzheimer’s disease (Figure 
I). 
 
Supplementary Figure 4 Healthy control logan VD values in the high affinity binders (Fig 
4A) and in comparison with mild cognitive impairment and Alzheimer’s disease in the 
composite cortex (Fig 4B). Figs 4C and 4D shows control data in the medium affinity 
binders, and comparison with the mild cognitive impairment and Alzheimer’s disease in the 
composite cortex.  
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Table 1 Demographics of the study cohort 
 Controls (n=19) Amyloid 
positive mild 
cognitive 
impairment 
(n=9) 
Amyloid negative 
mild cognitive 
impairment (n=7) 
Alzheimer’s 
disease (n=16) 
Age 64.22(8.52) 76.62(5.07)** 68.71(7.48) 73.69(7.15)* 
Years 
education 
13.37(3.34) 14.14(3.98) 11.25(0.96) 12.92(2.74) 
Mini Mental 
State 
Examination 
(total = 30) 
29.41(1.06) 28.33(1.22) 26.71(2.06)* 21.62(3.28)** 
Delayed 
visual recall 
(total = 36) 
18.18(7.12) 10.44(6.32)* 19.29(3.67) 5.19(6.33)** 
Delayed 
word list 
recall (total = 
12) 
10.21(2.04) 2.22(1.99)** 6.86(3.34)* 1.14(1.70)** 
Word list 
recognition 
(total = 12) 
11.27(1.03) 7.67(3.57) 8.29(3.63) 3.64(3.13) 
Semantic 
fluency 
20.73(6.00) 13.33(4.03)* 19.29(5.82) 10.93(6.13)** 
Trail-making 
A 
35.24(10.83) 51.22(11.71) 52.43(25.44)* 107.67(120> 
Trail-making 
B 
74.13(23.0) 171.67(106)** 116.33(39.80)** 148(46)* 
Right 
hippocampal 
volume 
(mm
3
) 
3860(407) 3398(574) 3669(477) 2827(549)** 
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Left 
hippocampal 
volume 
(mm
3
) 
3745(333) 3199(779)* 3662(267) 2743(400)** 
White matter 
hypointensity 
volume 
(mm
3
) 
2160(1208) 3693.5(1771) 9898(18658) 5153(3296)** 
** p<0.01, * p<0.05 
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Figure 1 Voxel level increases in 18F-flutemetamol (Fig 1A and 1B), 18F-AV1451 (Fig1C, 1D and 1E) and 
11C-PBR28 High Affinity Binders (Fig1F, 1G and 1H) compared to the healthy controls using independent t-
test in SPM. For 18F-flutemetamol and 11C-PBR28, a threshold of significance of p<0.05 was used. For 18F-
AV1451, a threshold of significance of p<0.01 was used. These images show the distribution of pathology in 
the mild cognitive impairment and Alzheimer’s disease groups  
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Figure 2 Voxel level correlations between tau and microglial activation in the amyloid positive mild cognitive 
impairment (Fig 2A), Alzheimer’s disease (Fig 2B) and amyloid negative cognitively impaired individuals (Fig 
2C)  
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Figure 3 Voxel level correlati ns between amyloid and microglial activation in the amyloid positive mild 
cognitive impairment (Fig 3A) and Alzheimer’s disease (Fig 3B) individuals  
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Individual levels of microglial activation correlated strongly with levels of both amyloid deposition and tau 
aggregation across the cortex, with Z-scores above 4 (Figure 4).  
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Figure 5 Individual parametric maps (Individual 1-9) of microglial activation (A) and tau aggregation (B) in 
the nine amyloid negative individuals with cognitive impairment, compared to the control mean. Clusters 
show trends of increased binding. Individuals 1,2,4,5 and 6 had statistically significant clusters of 18F-
AV1451 binding, while individuals 1,2,3,4 and 6 had statistically significant 11C-PBR28 binding compared to 
the control groups. This figure is provided to illustrate distributions of the pathologies in this small group of 
individuals.  
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Figure 6 The vicious cycle of activated microglia and protein aggregation. Activated microglia surround 
amyloid plaque and neurofibrillary tangles, and in turn promote upregulation of amyloid plaque and tangles. 
Further, the pro-inflammatory products of activated microglia promote further tau hyperphosphorylation and 
spreading of neurofibrillary tangles throughout the cortex  
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Supplementary Table 1 Clusters of positive correlations between 
11
C-PBR28, 
18
F-
AV1451 and 
18
F-flutemetamol  
Region of interest Montreal 
Neurological 
Institute 
Coordinates 
Z-score R 
correlation 
coefficient 
p-value Cluster size 
18
F-AV1451 and 
11
C-PBR28 
Mild cognitive impairment (Amyloid positive) 
Right superior frontal 
gyrus 
  5  -8 72 
 
4.49 0.990 <0.00001 49058 
Left superior frontal 
gyrus 
-14 51 41 
 
3.92 0.970 
Left middle frontal gyrus -36 61   0 
 
3.55 0.950 <0.00001 2118 
Right caudate 16 -12 21 
 
4.51 0.990 <0.00001 13813 
Corpus callosum   5   0 22 
 
4.16 0.980 
Right middle frontal 
gyrus 
19 23 10 
 
3.96 0.970 
Right anterior cingulate   8   6 29 
 
3.4 0.930 
Right superior frontal 
gyrus 
18 31 10 
 
3.3 0.930 
Left superior frontal 
gyrus 
-17 29 18 3.47 0.940 
Left precentral gyrus -19  -7 31 
 
3.43 0.940 
Left caudate -15 -12 22 
 
3.28 0.920 
Right superior parietal 
gyrus 
14 -50 18 
 
4.51 0.990 <0.00001 8830 
Right posterior temporal 
lobe 
28 -52   4 4.22 0.980 
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Left superior parietal 
gyrus 
-22 -42 24 
 
3.77 0.960 
Left posterior temporal 
lobe 
-22 -52   2 
 
4.32 0.980 
Corpus callosum 12 -45 16 
 
4.01 0.970 
Left thalamus -5 -19  -2 
 
4.37 0.980 <0.00001 3493 
Left fusiform gyrus -35 -16 -39 3.36 0.930 <0.00001 1548 
Right lateral orbital gyrus 39 48  -9 
 
3.18 0.910 <0.00001 2504 
Right middle frontal 
gyrus 
22 59  -5 
 
2.9 0.880 
Right superior frontal 
gyrus 
25 68   4 
 
2.77 0.860 
Left superior frontal 
gyrus 
-13 70 -4 3.9 0.970 <0.00001 560 
Left precentral gyrus 58 -2 43 3.21 0.920 <0.00001 826 
Right superior frontal 
gyrus 
10 70  -2 
 
3.36 0.930 <0.00001 1086 
Right medial orbital 
gyrus 
  9 64 -19 
 
2.86 0.880 
Left inferolateral part of 
PL 
-50 -46 53 
 
2.75 0.860 <0.00001 574 
Alzheimer’s disease (Amyloid positive) 
Right superior frontal 
gyrus 
16 42 53 
 
4.99 0.950 <0.00001 528779 
Right insula 43   3   1 
 
4.84 0.940 
Right anterior temporal 
lobe lateral part 
62   3 -21 
 
4.76 0.940 
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Right anterior temporal 
lobe medial part 
37   0 -48 
 
4.73 0.940 
Right inferior and 
temporal gyrus 
51  -4 -41 
 
4.89 0.950 
Left superior frontal 
gyrus 
-9   3 47 
 
4.85 0.940 
Left posterior temporal 
lobe 
-55 -43 12 4.89 0.950 
Left middle frontal gyrus -48 25 35 4.8 0.940 
Left caudate -16   7 21 
 
3.91 0.870 <0.00001 1337 
Left middle frontal gyrus -22 18 12 
 
2.91 0.740 
Left insula -25 16 10 
 
2.62 0.690 
Right superior parietal 
gyrus 
43 -41 63 
 
3.73 0.860 <0.00001 4844 
Right inferolateral part of 
parietal lobe 
43 -67 49 
 
3.33 0.810 
Right postcentral gyrus 37 -37 65 
 
2.59 0.690 
Right lateral part of 
occipital lobe 
42 -71 33 
 
2.48 0.660 
Right posterior temporal 
lobe 
23 -35 -18 
 
3.42 0.820 <0.00001 578 
Right fusiform gyrus 30 -32 -19 
 
3.05 0.770 
Right lateral part of 
occipital lobe 
41 -90  -3 
 
2.67 0.700 <0.00001 680 
Left amygdala -18  -2 -19 2.82 0.730 <0.00001 890 
Left anterior temporal 
lobe medial part 
-23 16 -38 
 
2.78 0.720 
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Left parahippocampus -13  -5 -24 2.72 0.710 
Left posterior orbital 
gyrus 
-24 13 -25 
 
2.38 0.640 
Left superior parietal 
gyrus 
  0 -66 43 
 
2.66 0.700 <0.00001 575 
Right superior parietal 
gyrus 
  5 -76 42 
 
2.63 0.690 
Amyloid negative individuals 
Right superior parietal 
gyrus 
33 -41 61 
 
3.41 0.940 0.003 1538 
Left posterior temporal 
lobe 
-46 -63 -16 3.4 0.930 <0.00001 3149 
Left lateral part of 
occipital lobe 
-42 -72 -14 2.72 0.860 
left superior frontal gyrus 11 48 34 2.57 0.830 0.031 1168 
11
C-PBR28 and 
18
F-flutemetamol      
Mild cognitive impairment (Amyloid positive) 
Right middle frontal 
gyrus 
15 44 -9  4.23 0.980 <0.00001 36790 
Right superior frontal 
gyrus 
16 44 0 4 0.970 
Corpus callosum 8 29 -1 3.67 0.950 
Right thalamus 3 -4 4  3.61 0.950 
Right pre-subgenual 
frontal cortex 
6 32 -3  3.59 0.950 
Right anterior orbital 
gyrus 
17 46 -14 3.46 0.940 
Right 
parahippocampus 
19 -10 -36 3.28 0.920 
Left pre-subgenual 
frontal cortex 
-2 37 -7 3.83 0.960 
Left superior frontal 
gyrus 
-13 46 -2 3.82 0.960 
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Left straight gyrus -3 21 -18 3.4 0.930 
Left anterior cingulate -9 43 -2 3.19 0.920 
Left medial orbital 
gyrus 
-14 45 -16 3.16 0.910 
Left middle frontal 
gyrus 
-19 38 1 3.14 0.910 
Left anterior orbital 
gyrus 
-16 47 -12 3.11 0.910 
Left parahippocampus -25 -14 -26 3.95 0.970 <0.00001 7541 
Left posterior 
temporal lobe 
-27 -53 -17 3.44 0.940 
Left thalamus -20 -29 2 3.37 0.930 
Left insula -26 -24 7 2.92 0.890 
Left caudate -17 8 12 2.78 0.870 
Left fusiform -33 -18 -29 2.23 0.770 
Left amygdala -20 -5 -18 2.15 0.750 
Right lateral part of 
occipital lobe 
12 -98 -1 3.75 0.960 <0.00001 2126 
Right cuneus 10 -95 8 2.74 0.860 
Left cuneus -2 -98 0 1.73 0.640 
Right posterior 
temporal lobe 
71 -44 -5 2.38 0.800 <0.00001 778 
Alzheimer’s disease (Amyloid positive) 
Left superior parietal 
gyrus 
-12 -67 64 3.64 0.850 <0.00001 20616 
Left inferolateral part 
of parietal lobe 
-37 -69 51 
 
3.36 0.810 
Left lateral part of 
occipital lobe 
-28 -83 23 
 
3.08 0.770 
Right precentral gyrus 32 -10 63 
 
4.28 0.910 <0.00001 829 
Right lateral part of 
occipital lobe 
50 -65   8 3.4 0.820 
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Right posterior 
temporal lobe 
63 -52 -11 
 
2.88 0.740 
Right inferolateral part 
of parietal lobe 
47 -56 30 
 
2.79 0.720 
Right posterior 
temporal lobe 
53 -60 13 3.49 0.830 <0.00001 9206 
Right lateral part of 
occipital lobe 
50 -65 8 3.4 0.820 
Right inferolateral part 
of parietal lobe 
47 -56 30 2.79 0.720 
Right superior parietal 
gyrus 
12 -43 63 
 
3.44 0.820 <0.00001 11745 
Right postcentral 
gyrus 
  9 -32 58 
 
3.44 0.820 
Right lateral part of 
occipital lobe 
22 -69 36 
 
3.03 0.760 
Right precentral gyrus 16 -21 63 
 
2.89 0.740 
Left superior parietal 
gyrus 
-1 -50 55 
 
3.1 0.770 
Left postcentral gyrus -1 -39 57 
 
2.86 0.730 
Left postcentral gyrus -40 -25 56 
 
3.42 0.820 <0.00001 686 
Left precentral gyrus -33 -27 60 
 
2.83 0.730 
Left precentral gyrus -57 7 32 2.96 0.750 <0.00001 729 
Left middle frontal 
gyrus 
-48 15 42 
 
2.45 0.660 
Right lateral part of 47 -77 25 2.03 0.570 <0.00001 713 
Page 47 of 93
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
occipital lobe  
Left inferolateral part  
of parietal lobe 
-54 -56 21 
 
2.75 0.720 <0.00001 629 
Left lateral part of 
occipital lobe 
-41 -71 17 
 
2.01 0.560 
Left superior frontal 
gyrus 
-16 -11 63 
 
2.72 0.710 <0.00001 590 
Left middle frontal 
gyrus 
-29   0 61 
 
2.31 0.630 
Left precentral gyrus -20 -16 62 
 
2 0.560 
Right lateral part of 
occipital lobe 
26 -85 -19 
 
2.07 0.580 <0.00001 509 
Left superior parietal 
gyrus 
-34 -47 52 
 
2.59 0.690 <0.00001 1276 
Left inferolateral part 
of parietal lobe 
-38 -45 45 
 
2.32 0.630 
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Region Coordinates Z-score  R 
correlation 
coefficient 
p-value Cluster 
size 
18
F-flutemetamol and 
11
C-PBR28 
Left precentral gyrus -57 -9 42 4.12 1.000 <0.00001 32243 
Left inferior frontal 
gyrus 
-47 39 -1 4.02 1.000 
Left middle frontal 
gyrus 
-28 64 9 3.79 1.000 
Right lateral orbital 
gyrus 
42 54 -16 3.77 1.000 
Left superior frontal 
gyrus 
-21 33 56 3.68 1.000 
Right middle frontal 
gyrus 
32 51 31 3.66 1.000 
Left superior temporal 
gyrus posterior part 
-68 -19 -2 3.56 1.000 
Left lateral orbital 
gyrus 
-49 44 -16 3.37 0.990 
Left middle and 
inferior temporal 
gyrus 
066 017 027 3.1 0.990 
Right inferior frontal 
gyrus 
58 27 24 3.03 0.980 
Left superior temporal 
gyrus posterior part 
063 07 04 3.03 0.980 
Right middle frontal 
gyrus 
38 57 3 3 0.980 
Right lateral orbital 
gyrus 
40 50 -19 2.99 0.980 
Corpus callosum -10 30 5 3.84 1.000 <0.00001 6635 
Right caudate 18 2- 13 3.59 1.000 
Right middle frontal 18 25 11 3.57 1.000 
Page 49 of 93
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
gyrus 
Right subgenual 
frontal cortex 
2 22 -6 3.27 0.990 
Right insula 21 26 3 0.980 
Left anterior temporal 
lobe medial part 
-34 19 -39 3.19 0.990 0.032 1323 
Left anterior temporal 
lobe lateral part 
-53 12 -29 2.75 0.970 
Left superior temporal 
gyrus anterior part 
-45 22 -27 2.52 0.950 
Left middle and 
inferior temporal 
gyrus 
-58 -2 -35 2.18 0.910 
Right posterior 
temporal lobe 
19 -36 5 3.03 0.980 0.011 1526 
Corpus callosum 15 -27 25 2.59 0.960 
Right superior parietal 
gyrus 
19 -30 29 2.56 0.960 
Corpus callosum -12 -17 29 2.98 0.980 <0.00001 2481 
Left postcentral gyrus -16 -18 31 2.64 0.960 
Left posterior 
cingulate cortex 
-9 -36 27 2.28 0.930 
Left precentral gyrus -57 -9 42 3.12 1.000 0.021 149 
Left postcentral gyrus -60 -14 37 2.92 0.980 
Left inferior frontal 
gyrus 
-47 39 -1 4.02 1.000 <0.00001 1249 
Left lateral orbital 
gyrus 
-49 44 -16 3.37 0.990 
Left middle frontal 
gyrus 
-48 49 -10 3.11 0.990 
Right thalamus 2 -12 3 3.81 1.000 <0.00001 602 
Left middle frontal 
gyrus 
-28 64 9 3.79 1.000 0.001 205 
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Right medial orbital 
gyrus 
42 54 -16 3.77 1.000 <0.00001 1704 
Right middle frontal 
gyrus 
38 57 3 3 0.980 
Right anterior orbital 
gyrus 
31 59 -7 2.67 0.970 
Right middle frontal 
gyrus 
32 51 31 3.66 1.000 0.022 148 
Right caudate  18 20 13 3.59 1.000 <0.00001 295 
Right middle frontal 
gyrus 
18 26 11 3.57 1.000 
Right insula 21 26 4 3 0.980 
Corpus callosum 16 30 6 2.94 0.980 
Left superior frontal 
gyrus 
-12 69 4 3.57 1.000 <0.00001 689 
Left superior temporal 
gyrus posterior part 
-68 -19 -2 3.56 1.000 <0.00001 739 
Left middle and 
inferior temporal 
gyrus 
-66 -17 -27 3.13 0.990 
Corpus callosum 0 25 -2 3.3 0.990 0.026 145 
Right subgenual 
frontal cortex 
2 22 -6 3.27 0.990 
18
F-AV1451 and 
11
C-PBR28 
Right middle frontal 
gyrus 
52 39 17 4.25 1.000 <0.00001 15651 
Right superior frontal 
gyrus 
13 68 13 3.99 1.000 
Right inferior frontal 
gyrus 
51 36 12 3.82 1.000 
Right anterior orbital 
gyrus 
25 65 -7 3.41 0.990 
Right lateral orbital 41 56 -7 2.93 0.980 
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gyrus 
Right posterior 
temporal lobe 
40 -50 4 3.75 1.000 <0.00001 2189 
Left superior frontal 
gyrus 
-17 25 62 3.63 1.000 <0.00001 10412 
Left middle frontal 
gyrus 
-46 48 15 3.07 0.990 
Left anterior orbital 
gyrus 
-23 65 -7 2.6 0.960 
Right superior frontal 
gyrus 
2 17 64 3.08 0.990 0.004 1592 
Left superior frontal 
gyrus 
-2 11 54 2.83 0.980 
Left inferolateral part 
of parietal lobe 
-32 -44 37 4.1 1.000 <0.00001 218 
Left superior parietal 
gyrus 
-25 -44 39 3.33 0.990 
Right superior frontal 
gyrus 
13 68 13 3.99 1.000 <0.00001 563 
Right anterior orbital 
gyrus 
25 65 -7 3.41 0.990 
Left posterior 
temporal lobe 
-49 -46 5 3.99 1.000 <0.00001 463 
Left middle and 
inferior temporal 
gyrus 
-50 -8 -39 3.99 1.000 <0.00001 727 
Left anterior temporal 
lobe lateral part 
-54 0 -39 2.92 0.980 
Right lateral occipital 
lobe 
29 -73 11 3.88 1.000 <0.00001 245 
Right middle frontal 
gyrus 
52 39 17 4.25 1.000 <0.00001 1257 
Right inferior frontal 51 36 12 3.82 1.000 
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gyrus 
Left inferolateral part 
of parietal lobe 
-32 -44 37 4.1 1.000 <0.00001 218 
Left superior parietal 
gyrus 
-25 -44 39 3.33 0.990 
Right superior frontal 
gyrus 
13 68 13 3.99 1.000 <0.00001 563 
Right anterior orbital 
gyrus 
25 65-7 3.41 0.990 
Left posterior 
temporal lobe 
-49 -46 5 3.99 1.000 <0.00001 463 
Left middle and 
inferior and temporal 
gyrus 
-50 -8 -39 3.99 1.000 <0.00001 727 
Left anterior temporal 
lobe lateral part 
-54 0 -39 2.92 0.980 
Right lateral occipital 
lobe 
29 -73 11 3.88 1.000 <0.00001 245 
Left superior temporal 
gyrus posterior part 
-52 -1 0 3.86 1.000 <0.00001 525 
Left precentral gyrus -61 4 15 3.84 1.000 
Right anterior 
temporal lobe medial 
part 
28 7 -30 3.79 1.000 0.007 156 
Left superior temporal 
gyrus posterior part 
-49 -9-1 3.74 1.000 <0.00001 229 
Right anterior 
temporal lobe medial 
part 
27 1 -47 3.68 1.000 <0.00001 256 
Right fusiform 32 -5 -45 2.52 0.950 
Left posterior 
temporal lobe 
-41 -42 -20 3.65 1.000 <0.00001 661 
Right superior parietal 15 -44 26 3.64 1.000 <0.00001 1325 
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gyrus 
Corpus callosum 19 -43 20 3.32 0.990 
Left anterior temporal 
lobe lateral part 
-56 4 -27 3.63 1.000 <0.00001 249 
Left lateral part of 
occipital lobe 
-50 -77 -9 3.62 1.000 <0.00001 843 
Right middle frontal 
gyrus 
39 56 -1 3.55 1.000 <0.00001 836 
Right inferior frontal 
gyrus 
53 42 -1 3.29 0.990 
Right lateral orbital 
gyrus 
41 56 -7 2.93 0.980 
Left superior temporal 
gyrus posterior part 
-37 -32 -8 3.5 0.990 0.007 156 
Left middle and 
inferior temporal 
gyrus 
-40 -32 -11 3.42 0.990 
Left superior frontal 
gyrus 
-18 58 34 3.5 0.990 0.002 179 
Left precentral gyrus -60 2 37 3.44 0.990 <0.00001 477 
Left superior frontal 
gyrus 
-14 67 17 3.32 0.990 <0.00001 720 
 
 
 
Page 54 of 93
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
Supplementary table 2  - Voxel level comparisons between the tracer 
positive individuals and healthy controls for each tracer 
 
 
11
C-PBR28 High affinity binders 
Region Coordinates Z-score p-value Cluster size 
Left middle and inferior 
temporal gyrus 
-44 -3 -32 4.69 <0.00001 1024962 
Right fusiform gyrus 32 -9 -38 4.63 
Left postcentral gyrus -16 -31 59 4.54 
Right middle and inferior 
temporal gyrus 
56 -28 -25 4.36 
Left posterior temporal 
lobe 
-49 -45 -9 4.28 
Right amygdala 29 -5 -26 4.28 
Right superior parietal 
gyrus 
24 -6038 4.27 
Left middle frontal gyrus -26 0 46 4.22 
Left lateral part of 
occipital lobe 
-28 -71 27 4.22 
Left superior parietal 
gyrus 
-21 -41 50 4.21 
Left postcentral gyrus -30 -31 48 4.2 
Left amygdala -23 -5 -29 4.18 
Left precentral gyrus -36 -12 34 4.17 
Right fusiform gyrus 32 -9 -38 4.63 0.003 1204 
Right anterior temporal 
lobe lateral part 
43 3 -37 4.16 
Right anterior temporal 
lobe medial part 
27 2 -41 3.8 
Right middle and inferior 
temporal gyrus 
36 -3 -41 3.66 
Left postcentral gyrus -16 -31 59 4.54 <0.00001 37439 
Left posterior temporal -49 -45 -9 4.28 
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lobe 
Left lateral part of 
occipital lobe 
-28 -71 27 4.22 
Left superior parietal 
gyrus 
-21 -41 50 4.21 
Right postcentral gyrus 34 -27 38 4.05 
Right superior parietal 
gyrus 
24 -60 38 4.27 <0.00001 3318 
Right inferolateral part of 
parietal lobe 
33 -49 36 4.02 
Left middle frontal gyrus -26 0 46 4.22 <0.00001 3556 
Left precentral gyrus -36 -12 34 4.17 
Left superior frontal gyrus -19 7 43 3.37 
Right precentral gyrus 14 -21 55 4.16 <0.00001 7260 
Right superior frontal 
gyrus 
8 -29 54 3.86 
Right middle frontal gyrus 30 11 38 3.78 
Right precentral gyrus 18 -23 60 3.6 
Left middle inferior 
temporal gyrus 
-51 -27 -27 4.14 <0.00001 1750 
Right middle and inferior 
temporal gyrus 
-52 -20 -23 3.9 
Left fusiform gyrus -41 -27 -23 3.4 
Left medial orbital gyrus -18 29 -18 3.94 <0.00001 2322 
Left posterior orbital 
gyrus 
-33 30 -7 3.85 
Left insula -29 27 -3 3.65 
Left putamen -19 15 -10 3.56 
Left nucleus accumbens -12 12 -9 3.37 
Left inferior frontal gyrus -44 34 -5 3.29 
Left middle frontal gyrus -23 24 -6 3.21 
Right lateral part of 
occipital lobe 
35 -83 -14 3.77 0.013 958 
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Left postcentral gyrus -45 -25 37 3.76 0.009 1012 
Left inferolateral part of 
parietal lobe 
-52 -23 27 3.62 
Left lingual gyrus -15 -78 -6 3.74 
Left lateral part of 
occipital lobe 
-17 -83 -13 3.45 
Right inferior frontal 
gyrus 
41 7 14 3.68 0.03 821 
Right insula 33 11 9 3.31 
18
F-flutemetamol 
Corpus callosum 2 -36 15 6.77 <0.00001 1031605 
Left posterior orbital 
gyrus 
-23 27 -23 6.7 
Right anterior cingulate 
cortex 
3 39 18 6.37 
Left medial orbital gyrus -13 28 -26 6.32 
Left superior frontal gyrus -3 36 35 6.26 
Right superior frontal 
gyrus 
2 51 9 6.21 
Left superior temporal 
gyrus anterior part 
-47 19 -20 6.2 
Left posterior cingulate 
cortex 
0 -20 28 6.2 
Right posterior orbital 
gyrus 
22 29 -24 6.17 
Right middle and inferior 
temporal gyrus 
60 -18 -18 6.16 
18
F-AV1451 
Corpus callosum -1 -17 26 5.13 <0.00001 997291 
Right anterior temporal 
gyrus, medial part 
23 8 -49 4.88 
Right superior parietal 
gyrus 
1 -42 39 4.73 
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Left anterior temporal 
gyrus medial part 
-22 6 -44 4.71 
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Region of interest Montreal 
Neurologica
l Institute 
Coordinates 
Z-
score 
R 
correlation 
coefficient 
Cluster 
size 
p-value 
18
F-flutemetamol and 
11
C-PBR28 - mild cognitive impairment individuals 
Right superior frontal 
gyrus 
13 46 -7 5 0.990 40707 <0.00001 
Right caudate 14 3 21 4.14 0.990 
Left anterior cingulate 
cortex 
-9 44 0 4.05 0.970 
Left superior frontal 
gyrus 
-13 46 1 4.03 0.970 
Right thalamus 18 -23 10 3.63 0.950 
Right pre-subgenual 
frontal cortex 
2 34 -3 3.51 0.940 
Right pallidum 17 -3-4 3.47 0.940 
Left thalamus -13 -15 1 3.42 0.940 
Left medial orbital gyrus 4 52 -12 3.36 0.930 
Left middle frontal gyrus -19 31 14 3.35 0.930 
Left superior frontal 
gyrus 
-17 37 12 3.31 0.930 
Left pre-subgenual 
frontal cortex 
-3 42 -4 3.3 0.930 
Right caudate 20 -18 21 3.26 0.920 
Corpus callosum 2 28 12 3.26 0.920 
Right straight gyrus 6 34 -18 3.25 0.920 
Left anterior cingulate 
cortex 
-4 33 12 3.21 0.920 
Left substantia nigra -11 -21 -13 4.12 0.980 <0.00001 5142 
Left posterior temporal 
lobe 
-27 -54 -17 3.73 0.960 
Left hippocampus -30 -33 -9 3.16 0.910 
Left posterior temporal 
lobe 
-25 -36 -2 3.08 0.900 
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Left parahippocampus -21 -28 -16 2.95 0.890 
Left superior temporal 
gyrus, posterior part 
-36 -29 3 2.93 0.890 
Left posterior temporal 
lobe 
-27 -35 -6 2.91 0.880 
Left lingual  -26 -54 -11 2.90 0.880 
Left insula -28 -28 12 2.90 0.880 
Left fusiform gyrus -38 -34 -16 2.68 0.850 
Left insula -33 -26 3 2.6 0.840 
Right inferior frontal 
gyrus 
-33 -28 9 2.49 0.820 
Left thalamus -16 -26 4 2.29 0.780 
Left superior temporal 
gyrus posterior part 
-37 -28 -1 2.21 0.760 
Left precentral gyrus -18 -23 58 3.48 0.940 
Left postcentral gyrus -13 -33 53 3.46 0.940 
Right superior frontal 
gyrus 
13 46 -7 5 0.990 <0.00001 1083 
Right medial orbital 
gyrus 
4 52 -12 3.36 0.930 
Right anterior cingulate 
cortex 
12 41 3 3.08 0.900 
Right middle frontal 
gyrus 
17 47 -6 2.68 0.850 
Right anterior orbital 
gyrus 
16 54 -16 2.51 0.820 
Right thalamus 3 -7 3 3.5 0.940 <0.00001 1966 
Right pallidum 17 -3 -4 3.47 0.940 
Right caudate 9 6 10 3.02 0.900 
Left thalamus -3 -9 2 2.99 0.890 
Left anterior cingulate 
cortex 
-9 44 0 4.05 0.970 <0.00001 3353 
Left superior frontal -13 46 1 4.03 0.970 
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gyrus 
Right pre-subgenual 
frontal cortex 
2 34 -3 3.51 0.940 
Right superior frontal 
gyrus 
5 45 -10 3.43 0.940 
Left middle frontal gyrus -19 31 14 3.35 0.930 
Left pre-subgenual 
frontal cortex 
-3 42 -4 3.3 0.930 
Right straight gyrus 6 34 -18 3.25 0.92 
Corpus callosum -13 34 3 3.17 0.910 
Right anterior cingulate 
cortex 
2 42 6 3.08 0.900 
Left middle frontal gyrus -22 34 11 3.04 0.900 
Left superior frontal 
gyrus 
5 42 -7 2.94 0.890 
Left medial orbital gyrus -10 52 -15 2.86 0.880 
Left anterior orbital 
gyrus 
-20 48 -10 2.82 0.870 
Left middle frontal gyrus -19 27 16 2.77 0.860 
Left anterior cingulate 
cortex 
-7 36 9 2.58 0.830 
18
F-flutemetamol and 
11
C-PBR28– Alzheimer’s disease subjects 
Right middle frontal 
gyrus 
21 35 0 3.95 0.880 <0.00001 26656 
Left thalamus -21 -26 -6 3.9 0.870 
Right straight gyrus 3 43 -21 3.64 0.850 
Right superior frontal 
gyrus 
3 43 -10 3.64 0.850 
Left caudate -15 8 12 3.43 0.820 
Right caudate 14 15 11 3.39 0.810 
Right middle frontal 
gyrus 
20 38 03 3.36 0.810 
Right anterior orbital 21 43 -8 3.32 0.800 
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gyrus 
Left medial orbital gyrus -9 45 -21 3.31 0.800 
Right insula 32 -27 -2 3.15 0.780 
Left fusiform -39 -27 -25 3.1 0.770 
Right putamen 26 -9 7 3.1 0.770 
Left superior frontal 
gyrus 
-1 44 -12 3.08 0.770 
Left pallidum -15 5 -2 2.96 0.750 
18
F-AV1451 and 
11
C-PBR28 – mild cognitive impairment subjects 
Right superior frontal 
gyrus 
13 41 39 4.54 0.990 1691 <0.00001 
Right posterior temporal 
lobe 
31 -57 4 4.54 0.990 135987 <0.00001 
Left superior frontal 
gyrus 
-3 -13 69 4.5 0.990 
Left superior parietal 
gyrus 
-40 -43 63 4.49 0.990 
Right superior frontal 
gyrus 
5 63 29 4.47 0.990 
Left middle frontal gyrus -43 56 -3 4.46 0.990 
Right precentral gyrus 4 -15 56 4.4 0.980 
Right postcentral gyrus 25 -18 35 4.3 0.980 
Right posterior temporal 
lobe 
27 -56 4 4.29 0.980 
Left precentral gyrus -3 -32 69 4.27 0.980 
Corpus callosum -9 25 7 4.23 0.980 
Right caudate 14 21 -1 4.22 0.980 
Right precentral gyrus 6 -15 75 4.19 0.980 
Left superior parietal 
gyrus 
-27 -57 66 4.19 0.980 
Right superior parietal 
gyrus 
25 -45 73 4.11 0.970 
Left anterior cingulate 0 6 39 4.08 0.970 
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cortex 
Right superior frontal 
gyrus 
3 -3 65 4.01 0.970 
Right postcentral gyrus 4 -30 57 4 0.970 
Left superior frontal 
gyrus 
-1 -5 55 4 0.970 
Right posterior cingulate 
cortex 
2 -25 27 3.98 0.970 
Right anterior orbital 
gyrus 
28 66 -8 3.94 0.970 
Left middle frontal gyrus -38 61 0 3.94 0.970 
Left lateral remainder of 
occipital lobe 
-27 -72 0 3.92 0.970 
Right postcentral gyrus 50 -15 34 3.9 0.970 
Right posterior temporal 
lobe 
23 -48 8 3.87 0.960 
Right lateral remainder 
of occipital lobe 
31 -61 3 3.86 0.960 
Left lateral remainder of 
occipital lobe 
-5 -101 -2 4.06 0.970 <0.00001 2561 
Left cuneus -7 -100 19 3.14 0.910 
Left lingual -3 -98 -5 2.52 0.820 
Left lateral remainder of 
occipital lobe 
-32 -90 14 1.92 0.690 
Right anterior temporal 
lobe medial part 
35 9 -28 3.59 0.950 <0.00001 2213 
Right anterior temporal 
lobe lateral part 
43 21 -37 3.56 0.950 
Right superior temporal 
gyrus anterior part 
42 24 -33 2.82 0.870 
Right fusiform gyrus 37 -31 -29 3.57 0.950 <0.00001 1155 
Right hippocampus 26 -18 -14 3.01 0.900 
Right amygdala 24 -9 -12 2.83 0.870 
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Right parahippocampus 23 -24 -16 2.65 0.850 
Right middle and 
inferior temporal gyrus 
41 -14 -20 2.29 0.780 
Right posterior temporal 
lobe 
41 -34 -29 2.26 0.780 
Right insula 35 -7 -17 1.76 0.650 
Left precentral gyrus -55 0 39 3.26 0.920 0.004 798 
Left middle frontal gyrus -50 2 52 2.15 0.750 
Right lateral remainder 
of occipital lobe 
31 -76 49 3.19 0.920 0.001 949 
Right inferolateral 
remainder of parietal 
lobe 
41 -71 43 2.86 0.880 
Right superior temporal 
gyrus anterior part 
52 14 -7 3.05 0.900 <0.0001 1118 
Right middle and 
inferior temporal gyrus 
64 1 -15 2.78 0.870 
Right superior temporal 
gyrus posterior part 
57 0 -16 2.28 0.780 
Right anterior temporal 
lobe lateral part 
60 8 -26 2.01 0.720 
Left middle frontal gyrus -38 54 22 2.84 0.870 0.019 674 
Right amygdala 16 0 -28 2.5 0.820 0.042 609 
Right fusiform gyrus 27 -13 -39 2.29 0.780 
Right parahippocampus 22 -12 -35 2.2 0.760 
Right superior frontal 
gyrus 
13 41 39 4.54 0.990 <0.00001 649 
Right posterior temporal 
lobe 
31 -57 4 4.54 0.990 <0.00001 1729 
Right lateral remainder 
of occipital lobe 
31 -61 3 3.86 0.960 
Right superior parietal 
gyrus 
18 -49 16 3.45 0.940 
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Right lingual gyrus 26 -62 1 2.54 0.830 
Left superior frontal 
gyrus 
-3 -13 69 4.5 0.990 <0.00001 1457 
Right precentral gyrus 4 -15 56 4.4 0.980 
Right superior frontal 
gyrus 
3 -3 65 4.01 0.970 
Left superior parietal 
gyrus 
-40 -43 63 4.49 0.990 <0.00001 665 
Left postcentral gyrus -48 -36 60 3.42 0.940 
Left inferolateral 
remainder of parietal 
lobe 
-49 -40 56 2.69 0.850 
Right superior frontal 
gyrus 
5 63 29 4.47 0.990 <0.00001 755 
Left superior frontal 
gyrus 
0 52 23 3.54 0.950 
Left precentral gyrus -3 -32 69 4.27 0.980 <0.00001 1523 
Left postcentral gyrus -17 -33 73 3.77 0.960 
Left superior parietal 
gyrus 
-17 -41 66 3.29 0.920 
Corpus callosum -9 25 7 4.23 0.980 <0.00001 4468 
Left lateral remainder of 
occipital lobe 
-27 -72 0 3.92 0.970 
Left middle frontal gyrus -21 4 26 3.69 0.950 
Left inferolateral 
remainder of parietal 
lobe 
-28 -22 25 3.65 0.950 
Left precentral gyrus -27 -11 29 3.56 0.950 
Left posterior temporal 
lobe 
-28 -54 2 3.51 0.940 
Left insula -22 -24 18 3.39 0.930 
Left superior frontal 
gyrus 
-13 24 24 3.23 0.920 
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Left lateral remainder of 
occipital lobe 
-29 -68 -4 3.13 0.910 
Left caudate -18 -20 24 3.1 0.910 
Left postcentral gyrus -32 -17 33 3.05 0.900 
Left middle frontal gyrus -18 6 24 3.01 0.900 
Left posterior temporal 
lobe 
-27 -61 4 2.98 0.890 
Right caudate 14 21 -1 4.22 0.980 <0.00001 1999 
Corpus callosum 17 30 9 3.18 0.910 
Right middle frontal 
gyrus 
20 15 21 3.14 0.910 
Right subgenual frontal 
cortex 
1 21 -4 3.13 0.910 
Right subcallosal area 1 14 -10 2.41 0.810 
Left anterior cingulate 
cortex 
0 6 39 4.08 0.970 <0.00001 753 
Left superior frontal 
gyrus 
-1 -5 55 4 0.970 
Right posterior cingulate 
cortex 
2 -25 27 3.98 0.970 <0.00001 637 
Corpus callosum 2 -31 18 3.71 0.960 
Left posterior cingulate 
cortex 
-4 -28 28 3.01 0.900 
Right anterior orbital 
gyrus 
28 66 -8 3.94 0.970 <0.00001 819 
Right middle frontal 
gyrus 
29 65 -4 3.51 0.940 
Right caudate 20 -18 21 3.83 0.960 <0.00001 948 
Right postcentral gyrus 25 -18 24 3.42 0.940 
Right inferolateral 
remainder of parietal 
lobe 
23 -24 24 3.42 0.940 
Right thalamus 12 -7 16 3.26  0.920 
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Corpus callosum -5 -13 24 2.81 0.870 
Corpus callosum 4 4 25 3.67 0.950 <0.00001 765 
Right anterior cingulate 11 3 33 2.68 0.850 
Right precentral gyrus 31 -24 66 3.47 0.940 <0.00001 586 
Right postcentral gyrus 43 -20 -56 3.23 0.920 
Tau and microglial activation – Alzheimer’s disease subjects 
Right middle frontal 
gyrus 
35 57 19 5.57 0.970 <0.00001 253556 
Right inferolateral part 
of parietal lobe 
64 -26 46 5.17 0.960 
Left anterior temporal 
lobe lateral part 
-60 4 -22 5.09 0.960 
Right anterior temporal 
lobe lateral part 
58 4 -27 5.08 0.960 
Left superior frontal 
gyrus 
-21 69 2 4.93 0.950 
Right superior frontal 
gyrus 
25 63 24 4.93 0.950 
Right postcentral gyrus 56 -17 55 4.69 0.940 
Left middle frontal gyrus -40 53 17 4.66 0.930 
Left posterior temporal 
lobe 
-55 -47 14 4.64 0.930 
Right superior temporal 
gyrus anterior part 
53 13 -20 4.64 0.930 
Right superior temporal 
gyrus posterior part 
65 2 -4 4.59 0.930 
Left precentral gyrus -46 -6 12 4.48 0.920 
Right posterior temporal 
lobe 
35 -51 -6 4.47 0.920 
Left middle and inferior 
temporal gyrus 
-42 -4 -46 4.46 0.920 
Left inferolateral 
remainder of parietal 
-68 -37 31 4.41 0.920 
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lobe 
Left superior parietal 
gyrus 
-2 -62 56 4.35 0.910 <0.00001 5272 
Right superior parietal 
gyrus 
6 -72 36 3.69 0.850 
Left postcentral gyrus -10 -39 77 3.15 0.780 
Left parahippocampus -25 -29 -22 3.41 0.820 0.001 595 
Left posterior temporal 
lobe 
-30 -41 -18 3.1 0.770 
Left inferolateral part of 
parietal lobe 
-30 -61 30 3.22 0.790 0.003 502 
Left superior parietal 
gyrus 
-25 -59 33 2.72 0.710 0.003 501 
Right middle frontal 
gyrus 
35 57 19 5.57 0.970 <0.00001 1506 
Right superior frontal 
gyrus 
25 63 24 4.93 0.950 
Left anterior temporal 
lobe lateral part 
-60 4 -22 5.09 0.960 <0.00001 4049 
Left middle and inferior 
temporal gyrus 
-42 -4 -46 4.46 0.920 
Left superior temporal 
gyrus posterior part 
-54 17 -8 3.73 0.860 
Right anterior temporal 
lobe lateral part 
58 4 -27 5.08 0.960 <0.00001 1467 
Right superior temporal 
gyrus posterior part 
65 2 -4 4.59 0.930 
Left superior frontal 
gyrus 
-21 69 2 4.93 0.950 <0.00001 1669 
Left middle frontal gyrus -40 53 17 4.66 0.930 
Left anterior orbital 
gyrus 
-28 65 -12 3.58 0.840 
Left posterior temporal -55 -47 14 4.64 0.930 <0.00001 8212 
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lobe 
Left inferolateral part of 
parietal lobe 
-68 -37 31 4.41 0.920 
Left superior temporal 
gyrus posterior part 
-58 -24 10 4.29 0.910 
Left middle and inferior 
temporal gyrus 
-70 -30 -4 3.71 0.850 
Left superior frontal 
gyrus 
-13 -2 62 4.5 0.920 <0.00001 1970 
Left precentral gyrus -46 -6 12 4.48 0.920 <0.00001 669 
Left insula -40 -10 8 3.56 0.840   
Left postcentral gyrus -44 -9 7 3.55 0.830 
Left superior temporal 
gyrus posterior part 
-51 1 -2 3.52 0.830 
Right superior temporal 
gyrus posterior part 
61 -24 3 4.45 0.920 <0.00001 7414 
Right posterior temporal 
lobe 
47 -35 3 4.37 0.910 
Right middle and 
inferior temporal gyrus 
65 -16 -14 4.3 0.910 
Right inferolateral part 
of parietal lobe 
52 -46 21 3.79 0.860 
Right superior parietal 
gyrus 
18 -45 30 4.04 0.890 <0.00001 984 
Corpus callosum 0 -26 26 3.98 0.880 
Right posterior cingulate 
cortex 
3 -44 22 3.37 0.810 
Right middle frontal 
gyrus 
27 34 21 4.03 0.890 <0.00001 551 
Right middle frontal 
gyrus 
35 57 19 5.57 0.970 <0.00001 663578 
Right inferolateral part 
of parietal lobe 
64 -26 46 5.17 0.960 
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Left anterior temporal 
lobe lateral part 
-60 4 -22 5.09 0.960 
Right anterior temporal 
lobe lateral part 
58 4 -27 5.08 0.960 
Left superior frontal 
gyrus 
-21 69 2 4.93 0.950 
Right superior frontal 
gyrus 
25 63 24 4.93 0.950 
Right postcentral gyrus 56 -17 55 4.69 0.940 
Left middle frontal gyrus -40 53 17 4.66 0.930 
Left posterior temporal 
lobe 
-55 -47 14 4.64 0.930 
Right superior temporal 
gyrus anterior part 
53 13 -20 4.64 0.930 
Right superior temporal 
gyrus posterior part 
65 2 -4 4.59 0.930 
Left precentral gyrus -46 -6 12 4.48 0.920 
Right posterior temporal 
lobe 
35 -51 -6 4.47 0.920 
Left middle and inferior 
temporal gyrus 
-42 -4 -46 4.46 0.920 
Left inferolateral part of 
parietal lobe 
-54 -21 17 4.36 0.910 
18
F-AV1451 and 
11
C-PBR28 - Amyloid negative individuals 
Left middle and inferior 
temporal gyrus 
-35 -4 -26 5.1 0.990 <0.00001 125462 
Left insula -35 -2 -19 4.84 0.990 
Right anterior temporal 
lobe lateral art 
51 4 -26 4.4 0.980 
Left posterior temporal 
lobe 
-21 -47 1 4.36 0.980 
Left inferolateral part of 
parietal lobe 
-37 -72 48 4.23 0.980 
Page 70 of 93
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
Right superior temporal 
gyrus anterior part 
51 10 -20 4.19 0.980 
Right lateral part of 
occipital lobe 
24 -66 18 4.01 0.970 
Left thalamus -6 -3 7 3.99 0.970 
Right fusiform gyrus 32 -17 -38 3.95 0.970 
Right inferolateral 
remainder of parietal 
lobe 
34 -65 53 3.88 0.970 
Right inferior frontal 
gyrus 
56 9 1 3.88 0.970 
Right superior parietal 
gyrus 
10 -51 73 3.88 0.960 
Right anterior temporal 
lobe medial part 
16 2 -31 3.86 0.960 
Left precentral gyrus -17 -12 75 3.82 0.960 
Left fusiform gyrus -36 -17 -22 3.82 0.960 
Left inferolateral part of 
parietal lobe 
-42 -46 52 3.8 0.960 
Right lateral part of 
occipital lobe 
23 -68 8 3.79 0.960 
Corpus callosum -12 -46 14 3.77 0.960 
Left insula -24 -28 15 3.76 0.960 
Right fusiform gyrus 28 -9 -42 3.75 0.960 
Left middle frontal gyrus -16 45 -4 3.75 0.960 
Left postcentral gyrus -18 -28 75 3.74 0.960 
Left inferior frontal 
gyrus 
-53 11 20 4.89 0.990 0.001 1956 
Left precentral gyrus -45 2 15 3.35 0.930 
Left middle frontal gyrus -49 9 44 2.34 0.790 
Right middle frontal 
gyrus 
25 56 16 3.85 0.960 <0.00001 2352 
Right superior frontal 18 63 16 2.43 0.81 
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gyrus 
Right anterior temporal 
lobe lateral part 
51 4 -26 4.4 0.980 <0.00001 3121 
Right superior temporal 
gyrus anterior part 
51 10 -20 4.19 0.980 
Right inferior frontal 
gyrus 
56 9 1 3.88 0.970 
Right anterior temporal 
lobe medial part 
36 12 -40 3.62 0.950 
Right middle and 
inferior temporal gyrus 
53 -5 -19 3.58 0.950 
Right superior temporal 
gyrus posterior part 
65 2 -7 2.93 0.890 
Left posterior temporal 
lobe 
-21 -47 1 4.36 0.980 <0.00001 3275 
Left lateral remainder of 
occipital lobe 
-27 -73 -1 3.59 0.950 
Left lingual gyrus -26 -65 -3 3.59 0.950 
Left middle and inferior 
temporal gyrus 
-40 -31 -10 2.7 0.850 
Right insula 27 18 2 4.04 0.970 
Right posterior orbital 
gyrus 
26 25 -12 4 0.970 
Right putamen 24 14 -4 2.72 0.860 
Right insula 27 18 2 4.03 0.970 <0.00001 722 
Right posterior orbital 
gyrus 
26 25 -12 4 0.970 
Right putamen 24 14 -4 2.72 0.860 
Left middle frontal gyrus -16 45 -4 3.75 0.960 <0.00001 1630 
Corpus callosum -13 31 11 3.62 0.950 
Left anterior cingulate 
cortex 
-5 6 33 3.44 0.940 
Left medial orbital gyrus -5 37 -17 3.31 0.930 
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 Left superior frontal 
gyrus 
-16 29 20 2.97 0.890 
Left pre-subgenual 
frontal cortex 
-6 36 -11 2.52 0.820 
Left subgenual frontal 
cortex 
-7 31 -10 2.44 0.810 
Left middle frontal gyrus -15 34 -4 2.39 0.800 
Left middle frontal gyrus -16 45 -4 3.75 0.960 <0.00001 1630 
Corpus callosum -13 31 11 3.62 0.950 
Left anterior cingulate 
cortex 
-5 6 33 3.44 0.940 
Left medial orbital gyrus -5 37 -17 3.31 0.930 
Left superior frontal 
gyrus 
-16 29 20 2.97 0.890 
Left pre-subgenual 
frontal cortex 
-6 36 -11 2.52 0.820 
Left subgenual frontal 
cortex 
-7 31 -10 2.44 0.810 
Right lateral remainder 
of occipital lobe 
20 -83 6 3.26 0.920 <0.00001 512 
Right lingual gyrus 14 -81 6 2.75 0.860 
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Subject Region Coordinates Z score p-value Cluster 
size 
AD1 – 
11
C-
PBR28 
Left superior parietal gyrus -27 -39 48 3.35 <0.00001 24158 
 Left posterior temporal lobe -47 -51 5 3.09   
 Left lateral remainder of 
occipital lobe 
-29 -82 15 3.08   
 Left postcentral gyrus -26 -35 47 3.02   
AD1 – 
18
F-
AV1451 
 Right superior parietal 
gyrus 
2 -51 16 6.31 <0.00001 776294 
 Right posterior temporal 
lobe 
49 -60 2 6.29   
 Right lateral part of 
occipital lobe 
37 -73 -19 5.92   
 Left middle and inferior 
temporal gyrus 
-63 -13 -26 5.87   
 Corpus callosum 5 -42 11 5.82   
AD2 – 
11
C 
PBR28 
Right superior parietal 
gyrus 
18 -45 -40 4.28 <0.00001 681404 
 Right posterior temporal 
lobe 
36 -58 8 4.2   
 Left middle frontal gyrus -25 33 13 4.12   
 Left superior parietal gyrus -16 -52 44 4.05   
 Right lateral remainder of 
occipital lobe 
41 -63 9 3.99   
 Left inferolateral remainder 
o parietal lobe 
-47 -50 34 3.99   
 Right precentral gyrus 23 -22 46 3.92   
 Right superior frontal gyrus 17 -6 51 3.91   
 Right middle and inferior 
temporal gyrus 
36 -7 -43 3.89   
 Right inferolateral 
remainder of parietal lobe 
49 -44 32 3.89   
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 Left superior parietal gyrus -10 -46 35 3.87   
 Left lingual gyrus -11 -47 -3 3.86   
AD2 – 
18
F-
AV1451 
 
Left posterior temporal lobe -51 -44 7 6.01 <0.00001 572923 
 Left middle and inferior 
frontal gyrus 
-64 -24 -6 5.86   
 Left posterior cingulate 
cortex 
-2 -40 25 5.85   
 Left superior temporal 
gyrus posterior part 
-64 -28 5 5.81   
 Right posterior temporal 
lobe 
54 -37 -4 5.78   
 Right superior parietal 
gyrus 
2 -50 17 5.76   
 Right middle and inferior 
temporal gyrus 
66 -20 -21 5.69   
AD3 – 
11
C -
PBR28  
Right insula 36 -12 -9 4.53 <0.00001 363635 
 Right middle frontal gyrus 21 10 35 4.24   
 Right fusiform gyrus 31 -9 -37 4.09   
 Left inferolateral remainder 
of parietal lobe 
-34 -24 31 3.95   
 Left middle frontal gyrus -25 37 -5 3.91   
 Right parahippocampus 26 -9 -34 3.89   
 Left posterior temporal lobe -37 -36 0 3.85   
 Right inferolateral 
remainder of PL 
41 -33 28 3.71   
 Left middle frontal gyrus -21 44 3 3.66   
 Right posterior temporal 
lobe 
48 -38 -15 3.66   
AD3 –
18
F- 
AV1451 
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 Left middle and inferior 
temporal gyrus 
-62 -13 -27 5.41 <0.00001 294532 
 Right superior parietal 
gyrus 
2 -50 17 5.06   
 Left posterior temporal lobe -57 -33 1 4.98   
 Right middle inferior gyrus 27 62 10 4.58   
 Left medial orbital gyrus -6 61 -19 4.54   
 Left posterior cingulate 
cortex 
-2 -40 25 4.51   
 Right middle and inferior 
temporal gyrus 
56 -17 -22 4.77 0.005 51510 
 Right posterior temporal 
lobe 
55 -37 -3 4.14   
AD4 – 
11
C -
PBR28 
 
Left anterior temporal lobe 
medial part 
-26 1 -49 4.72 <0.00001 1000336 
 Right inferolateral 
remainder of parietal lobe 
32 -52 37 4.67   
 Right anterior temporal 
lobe lateral part 
41 14 -37    
 Left posterior temporal lobe -63 -42 -23 4.6   
 Right posterior cingulate 
cortex 
2 -21 44 4.59   
 Right posterior temporal 
lobe 
66 -46 -2 4.58   
 Left parahippocampus -27 -14 -30 4,55   
 Left middle and inferior 
temporal gyrus 
-37 -3 -42 4.53   
AD4 – 
18
F-
AV1451 
 
Left middle and inferior 
temporal gyrus 
-63 -14 -25 6.14 <0.00001 291873 
 Left superior temporal 
gyrus posterior part 
-64 -24 -6 5.44   
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 Left posterior temporal lobe -62 -37 -3 5.44   
 Right middle and inferior 
temporal gyrus 
66 -20 -20 5.41 <0.00001 96228 
 Right posterior temporal 
lobe 
67 -34 -11 5.15   
 Right anterior temporal 
lobe lateral part 
57 10 -25 4.58   
AD5 – 
11
C -
PBR28 
Right hippocampus 31 -30 -6 4.91 0.034 15117 
 Right middle and inferior 
temporal gyrus 
43 -22 -12 2.64   
 Right parahippocampus 30 -24 -24 2.6   
 Right thalamus 18 -20 6 2.53   
 Right fusiform 35 -8 -30 2.5   
 Right posterior temporal 
lobe 
50 -43 -12 2.46   
 Right anterior temporal 
lobe medial part 
37 3 -33 2.43   
AD5 – 
18
F-
AV1451 
 
Left middle and inferior 
temporal gyrus 
-62 -3 -31 5.21 <0.00001 407247 
 Left posterior cingulate 
cortex 
-2 -41 27 5   
 Left lateral part of occipital 
lobe 
-40 -69 -3 4.76   
 Right middle frontal gyrus 39 18 32 4.76   
 Left middle frontal gyrus -24 30 38 4.72   
 Left medial orbital gyrus -5 62 -21 4.55   
 Right middle and inferior 
temporal gyrus 
56 -17 -22 4.52   
 Left posterior temporal lobe -39 -63 16 4.49   
 Right middle frontal gyrus 39 18 32 4.76 <0.00001 38842 
 Right superior frontal gyrus 20 23 44 4.43   
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 Left inferior frontal gyrus -40 32 12 3.09   
 Left superior frontal gyrus -22 67 5 3.01   
 Left anterior orbital gyrus -31 64 -6 2.74   
AD6 – 
18
F-
AV1451 only 
Left lateral part of occipital 
lobe 
-42 -67 -1 4.96 <0.00001 109095 
 Left posterior temporal lobe -39 -63 16 4.94   
 Left middle and inferior 
temporal gyrus 
-63 -12 -31 4.24   
 Right posterior temporal 
lobe 
45 -62 6 4.17   
 Corpus callosum 1 -28 17 3.99   
 Left inferolateral part of 
occipital lobe 
Left 
inferolateral 
part of 
occipital lobe 
-60 -27 
20 
3.95  
 Right middle and inferior 
temporal gyrus 
50 -10 -45 3.9   
 Left lateral part of occipital 
lobe 
-42 -67 -1 4.96 <0.00001 23218 
 Left posterior temporal lobe -47 -63 -10 4.08   
 Left inferolateral part of 
parietal lobe 
-32 -49 28 5.19   
AD7 – 
18
F-
AV1451 
Only 
Left posterior temporal lobe  5.35 <0.00001 221890 
 Left lateral part of occipital 
lobe 
 5.01   
 Right posterior temporal 
lobe 
 4.81   
AD8 
18
F-
AV1451 
Only 
Right lingual gyrus 17 -74 3 4.79 0.002 59276 
 Right posterior temporal 47 -65 -20 4.56   
Page 78 of 93
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
lobe 
 Right lateral part of 
occipital lobe 
38 -73 -20 4.17   
 Right superior parietal 
gyrus 
7 -55 16 3.74   
 Right cuneus 22 -64 17 3.7   
AD9 – 
18
F-
AV1451 
Only 
Left lateral part of occipital 
lobe 
-33 -88 31 4.14 0.035 36365 
 Left inferolateral part of 
parietal lobe 
-49 -76 33 3.99   
 Left superior parietal gyrus -43 -44 57 3.87   
AD10 – 
18
F-
AV1451 only 
 
Left middle and inferior 
temporal gyrus 
 5.76 <0.00001 249033 
 Let posterior temporal lobe  5.24   
 Left inferolateral part of 
parietal lobe 
 4.35   
 Left anterior temporal lobe 
medial part 
 4.24   
 Left superior temporal 
gyrus posterior part 
 4.2   
 Left inferolateral par of 
parietal lobe 
-39 -63 47 3.66 0.007 48761 
 Left superior parietal gyrus -31 -60 55 3.55   
 Right superior parietal 
gyrus 
28 -51 65 3.34   
 Right postcentral gyrus 52 -20 61 3.02   
 Right inferolateral 
remainder of parietal lobe 
11 -40 73 2.92   
AV11-
18
F-
AV1451 
Only 
Right superior parietal 
gyrus 
2 -50 17 6.33 <0.00001 768730 
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 Right posterior temporal 
lobe 
50 -56 -24 6.11   
 Left posterior cingulate 
cortex 
-2 -40 26 6.04   
 Left middle and inferior 
temporal gyrus 
-63 -14 -25 5.96   
 Left posterior temporal lobe -39 -63 16 5.86   
 Corpus callosum 1 -28 17 5.8   
 Left precentral gyrus -25 -25 58 5.73   
 Right posterior cingulate 
cortex 
5 -46 33 5.69   
AD12 – 
18
F-
AV1451 only 
Right superior parietal 
gyrus 
2 -50 17 6.49 <0.00001 871963 
 Left precentral gyrus -14 -54 -10 6.16   
 Left posterior cingulate 
cortex 
-2 -40 26 6.09   
 Corpus callosum 1 -28 17 6.08   
 Right lingual gyrus 3 -66 0 6.03   
 Left middle and inferior 
temporal gyrus 
-63 -14 -25 5.92   
 Left superior parietal gyrus -1 -56 10 5.89   
 Left posterior temporal lobe -39 -63 16 5.83   
AD13 – 
18
F-
AV1451 only 
Left posterior temporal lobe -55 -55 -23 5.54 <0.00001 271287 
 Right lateral part of 
occipital lobe 
37 -72 -19 5.46   
 Right posterior temporal 
lobe 
50 -55 -24 5.22   
 Left middle and inferior 
temporal gyrus 
-63 -13 -26 5.14   
 Left lateral part of occipital 
lobe 
-40 -69 -4 5.06   
 Right lingual gyrus 2 -79 -8 5   
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MCI 1– 
18
F-
AV1451 only 
Left posterior temporal lobe -54 -56 -24 4.69 0.007 9696 
 Left lateral remainder of 
occipital lobe 
-35 -73 20 4.42   
 Left middle and inferior 
temporal gyrus 
-55 -23 -15 3.38   
MCI2 – 
18
F-
AV1451 only 
     
 Left middle frontal gyrus -45 3 53 5.43 <0.00001 1171879 
 Right middle frontal gyrus 35 43 31 5.4   
 Right superior frontal gyrus 17 38 52 5.26   
 Right inferolateral part of 
parietal lobe 
43 -65 46 5.24   
 Left parahippocampus -17 -8 -28 5.16   
 Left middle and inferior 
temporal gyrus 
-41 -10 -45 5.09   
MCI3 – 
18
F-
AV1451 only 
Right superior parietal 
gyrus 
10 -61 27 5.13 0.008 48106 
 Right middle and inferior 
temporal gyrus 
62 -19 -34 4.19   
 Right parahippocampus 25 -22 18 3.9   
 Right fusiform gyrus 38 -14 -36 3.76   
 Right posterior temporal 
lobe 
48 9 -46 3.58   
MCi4 – 
18
F-
AV1451 only 
Right posterior temporal 
lobe 
-55 -55 -23 5.7 <0.00001 314428 
 Right superior parietal 
gyrus 
9 -61 27  5.59   
 Left posterior temporal lobe -59 -45 -27 5.58   
 Left superior temporal 
gyrus posterior part 
-64 -29 5 5.37   
 Left middle and inferior 
temporal gyrus 
-63 -13 -26 5.22   
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 Left inferolateral part of 
parietal lobe 
-56 -41 21  5.13   
 Left lateral part of occipital 
lobe 
-43 -67 0 5.04   
MCI5 – 
11
C -
PBR28 only 
Left anterior temporal lobe 
lateral part 
-59 8 -24 3.81 <0.00001 5586 
 Left middle and inferior 
temporal gyrus 
-65 -5 -24 3.69 <0.00001 5586 
MCI6 – 
11
C -
PBR28 only 
Right fusiform gyrus 27 -4 -47 3.49 0.04 13309 
 Brainstem 10 -35 -19 3.84 <0.00001 66332 
 Left hippocampus -20  -13 -16 3.82   
 Left posterio  temporal lobe -52 -37 -13 3,55   
 Left anterior temporal lobe 
medial part 
-30 5 -30 3.5   
 Left parahippocampus -24 -3 -38 3.47   
 Left posterior temporal lobe 13 -42 -3 3.17   
MCI7 – 
11
C -
PBR28 
Right parahippocampus 25 -24 -17 3.07 0.007 19319 
 Right superior temporal 
gyrus posterior part 
41 -22 -8 3.01   
 Right fusiform gyrus 40 -18 -26 2.99   
 Right middle and inferior 
temporal gyrus 
42 -13 -19 2.89   
MCI7 – 
18
F-
AV1451 
Corpus callosum 5 -42 11 4.41   
 Right superior parietal 
gyrus 
3 -51 16 4.36   
 Left posterior cingulate 
cortex 
-2 -44 30 4   
 Right posterior cingulate 
cortex 
4 -47 33 3.76   
 Right posterior cingulate 5 -4 45 4.15 <0.00001 2493 
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 Corpus callosum 7 1 29 3.97   
 Left posterior cingulate 
cortex 
0 -19 47 3.71   
 Left anterior cingulate 
cortex 
-6 -2 30 3.49   
 Left posterior temporal lobe -58 -53 -3 4.03 <0.00001 3874 
MCI8 -
18
F-
AV1451 
     
 Left middle and inferior 
temporal gyrus 
-63 -14 -25 3.49 <0.00001 35715 
 Right lateral part of 
occipital lobe 
25 -79 38 3.41 <0.00001 72911 
 Right inferolateral part of 
parietal lobe 
62 -38 48 3.35   
 Left inferolateral part of 
parietal lobe 
-48 -61 47 3.11 <0.00001 48056 
 Left superior parietal gyrus -33 -60 55 3.07   
AMY NEG1 
– 
11
C -
PBR28 
Right middle frontal gyrus 21 38 13 5.37 <0.00001 1398526 
 Left postcentral gyrus -12 -34 64 5.33   
 Right middle and inferior 
temporal gyrus 
49 -10 -31 5.08   
AMY NEG 1 
– 
18
F-
AV1451 
Right postcentral gyrus 52 -20 61 3.73 0.002 61430 
 Right inferolateral part of 
parietal lobe 
61 -34 52 3.62   
 Left inferolateral part of 
parietal lobe 
-50 -30 52 3.43   
 Left superior parietal gyrus -31 -59 55 3.38   
 Left lateral part of occipital -27 -98 10 3.38   
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 Right middle frontal gyrus 42 13 59 3.33   
 Right superior frontal gyrus 22 19 64 3.26   
 Left postcentral gyrus -42 -38 65 3.23   
AMY NEG 2 
– 
11
C -
PBR28 
Left straight gyrus -7 13 -17 4.57 <0.00001 47101 
 Right anterior temporal 
lobe lateral part 
45 8 -38 4.46   
 Right fusiform gyrus 33 0 -30 3.68   
 Right middle and inferior 
temporal gyrus 
47 -3 -35 3.66   
 Right posterior temporal 
lobe 
50 -41 6 3.49   
 Right anterior temporal 
lobe medial part 
39 0 -42 3.46   
 Right straight gyrus 6 10 -18 3.43   
 Left putamen -21 7 -3 3.4   
 Left medial orbital gyrus -11 13 -22 3.33   
 Left superior frontal gyrus -12 37 42 3.61 <0.00001 24774 
 Right posterior cingulate 
cortex 
10 -18 34 3.39   
 Left precentral gyrus -19 -18 56 3.19   
 Left anterior cingulate 
cortex 
-3 18 28 3.12   
 Right superior frontal gyrus 10 27 38 3.09   
 Right anterior cingulate 
cortex 
3 -2 35 3.08   
 Left posterior cingulate 
cortex 
-7 -15 35 3.05   
 Left anterior cingulate 
cortex 
-4 -1 42 2.96   
 Left superior parietal gyrus -9 -48 59 2.95   
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 Left superior parietal gyrus -9 -48 59 2.95   
 Left superior frontal gyrus -5 3 64 2.92   
AMY NEG 2 
– 
18
F-
AV1451  
Left anterior temporal lobe 
medial part 
-23 12 -40 2.49 0.008 20633 
AMY NEG 3  
-
11
C- PBR28 
Right postcentral gyrus 34 -27 43 3.81 <0.00001 31528 
 Right precentral gyrus 36 -23 49 3.72   
 Left superior parietal gyrus -19 -39 68 3.65   
 Right superior parietal 
gyrus 
31 -36 56 3.63   
 Right superior parietal 
gyrus 
17 -48 56 3.54   
 Left inferolateral remainder 
of parietal lobe 
-54 -28 47 3.52   
 Right superior frontal gyrus 9 -4 60 3.49   
 Left precentral gyrus -34 -20 51 3.44   
 Right inferolateral 
remainder of parietal lobe 
37 -65 40 3.4   
 Left postcentral gyrus -18 -38 62 3.32   
 Right middle and inferior 
temporal gyrus 
66 -23 -22 3.32 0.007 3730 
 Right precentral gyrus 59 -1 9 2.86   
 Right superior temporal 
gyrus posterior part 
65 1 0 2.8   
 Left lingual gyrus -8 -86 -5 2.82 0.018 3262 
 Right cuneus 5 -92 9 2.74   
 Left cuneus -2 -91 -1 2.68   
 Right superior temporal 
gyrus posterior part 
53 1 -13 3.47 0.002 4545 
 Right superior temporal 
gyrus anterior part 
48 18 -22 3.45   
 Right middle frontal gyrus 23 51 -4 3.41   
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 Right anterior temporal 
lobe medial part 
38 10 -25 3.13   
 Right inferior frontal gyrus 48 36 -9 2.89   
AMY NEG 3  
- 
18
F-AV1451 
Right superior frontal gyrus 22 20 63 4.91 <0.00001 132871 
 Left precentral gyrus -25 -25 58 4.74   
 Right middle frontal gyrus 54 19 41 4.69   
      
 Left superior frontal gurus -13 28 60 4.37   
 Left middle frontal gyrus -28 2 65 4.34   
 Right precentral gyrus 59 7 40 4.29   
AMY NEG 4 
– 
11
C -
PBR28 
Right middle and inferior 
temporal gyrus 
44 -31 -12 4.07 <0.00001 30488 
 Right posterior temporal 
lobe 
44 -35 -15 3.12   
AMY NEG 5 
– 
11
C -
PBR28 
Left insula -33 15 6 4.77 <0.00001 909967 
 Right middle frontal gyrus 21 38 -8 4.68   
AMY NEG 6 
– 
18
F-
AV1451 
Right lingual gyrus 2 -81 -7 4.52 <0.00001 279556 
 Left precentral gyrus -25 -25 58 4.32   
 Right superior frontal gyrus 24 20 63 4.25   
 Right middle frontal gyrus 43 13 54 4.06   
 Right precentral gyrus 69 -5 25 3.9   
 Left postcentral gyrus -26 -29 61 3.89   
 Left superior parietal gyrus -1 -52 64 3.86   
 Left posterior temporal lobe -60 -53 -4 3.85   
 Right inferolateral part of 
parietal lobe 
65 -43 27 3.79   
 Right superior parietal 18 -55 58 3.77   
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